

06.12.2023

08:30 - 12:00 **Type: Special session** **Room C**
Title: Joint ESMO-SITC Immunotherapy Primer
Moderation: Aurelien Marabelle, France; Jennifer Guerriero, United States of America

08:30 - 08:35 **Welcome and introduction**

All Speakers, Geneva, Switzerland

08:35 - 08:55 **Principles of tumour immunity**

Bernard A. Fox, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, United States of America

08:55 - 09:00 **Q&A**

All Speakers, Geneva, Switzerland

09:00 - 09:20 **Neutralizing the wrong type of tumor inflammation**

Ignacio Melero, Clinica Universidad de Navarra, Pamplona, Spain

09:20 - 09:25 **Q&A**

All Speakers, Geneva, Switzerland

09:25 - 09:45 **Myeloid cells as critical players in the TME**

Jennifer Guerriero, Brigham and Women's Hospital, Boston, United States of America

09:45 - 09:50 **Q&A**

All Speakers, Geneva, Switzerland

09:50 - 10:20 **Break**

10:20 - 10:40 **TIL-based therapy**

George Coukos, UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, Switzerland

10:40 - 10:45 **Q&A**

All Speakers, Geneva, Switzerland

10:45 - 11:05 **Cancer vaccines 2.0**

Stephen Schoenberger, La Jolla Institute for Immunology, La Jolla, United States of America

11:05 - 11:10 **Q&A**

All Speakers, Geneva, Switzerland

11:10 - 11:30	The microbiome influence on the TME <u>Laurence Zitvogel</u> , Institut Gustave Roussy, Villejuif, France	
11:30 - 11:35	Q&A <u>All Speakers</u> , Geneva, Switzerland	
11:35 - 11:55	Panel discussion <u>All Speakers</u> , Geneva, Switzerland	
11:55 - 12:00	Conclusions <u>All Speakers</u> , Geneva, Switzerland	
12:00 - 13:00	Type: Industry Satellite Symposium Title: Regeneron Pharmaceuticals - The future of non-melanoma skin cancer treatment: From molecular insights to clinical strategies	Room A
12:00 - 12:02	Welcome and Introduction <u>Javier Cañueto</u> , University Hospital of Salamanca, Salamanca, Spain	
12:02 - 12:17	Immune checkpoint blockade in advanced BCC and CSCC <u>Christoffer Gebhardt</u> , University Medical Center Hamburg-Eppendorf, Hamburg, Germany	
12:17 - 12:32	Immunotherapy response and tumor microenvironment in non-melanoma skin cancer <u>Charlotte Zuur</u> , The Netherlands Cancer Institute, Amsterdam, Netherlands	
12:32 - 12:47	Clinical case discussions and future therapeutic strategies for NMSC <u>Javier Cañueto</u> , University Hospital of Salamanca, Salamanca, Spain	
12:47 - 13:00	Panel discussion <u>All Speakers</u> , Geneva, Switzerland	

13:30 - 14:05	Type: Keynote address Title: Opening session and 2023 Award Moderation: Michele Maio, Italy; Aurelien Marabelle, France	Room B
13:30 - 13:35	Welcome to the ESMO Immuno-Oncology Congress 2023 <u>Michele Maio</u> , AOU Senese - Santa Maria delle Scotte, Siena, Italy	
13:35 - 13:40	Introduction to the 2023 Award keynote lecture <u>Aurelien Marabelle</u> , Institut Gustave Roussy, Villejuif, France	
13:40 - 14:05	Lymphocytes as a “living drug” for the treatment of cancer <u>Steve A. Rosenberg</u> , National Cancer Institute in Bethesda, Bethesda, United States of America	
14:15 - 15:45	Type: Educational session Title: Leveraging insights from basic cancer immunology for translation Moderation: Nikhil Joshi, United States of America; Amy Moran, United States of America	Room A
14:15 - 14:35	Role of androgen receptor activity in T cell inhibition and potential for therapeutic intervention <u>Amy Moran</u> , OHSU - Oregon Health Science University, Portland, United States of America	
14:35 - 14:55	Understanding T cell locations and targetable reservoirs for therapeutic modulation <u>Nikhil Joshi</u> , Yale University School of Medicine, New Heaven, United States of America	
14:55 - 15:15	Understanding and manipulating cytokine activities in different extracellular microenvironments <u>Suman Mitra</u> , CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, France	
15:15 - 15:35	Understanding CAR-T cell immunobiology as a means to improving therapeutic efficacy <u>Sebastian Kobold</u> , LMU Klinikum der Universität München, Munich, Germany	
15:35 - 15:45	Q&A and discussion <u>All Speakers</u> , Geneva, Switzerland	
14:15 - 15:45	Type: Abstract session Title: Proffered Paper session 1 Moderation: Aurelien Marabelle, France; Solange Peters, Switzerland	Room B
14:15 - 14:25	1180 - Definitive results for NSCLC and Bladder cancer cohorts in the phase 2a trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1	

relapsed/refractory solid tumors (GDFATHER-trial)

Ignacio Melero¹, M.J. De Miguel², G. Alonso Casal³, G.A. De Velasco Oria⁴, E. Ramelyte⁵, M. Joerger⁶, J. Martin-Liberal⁷, D. König⁸, C.M. Sayehli⁹, T. Gromke¹⁰, M. Rodríguez-Ruiz¹, E. Calvo², E. Garralda¹¹, J.J. Soto-Castillo⁷, R. Dummer¹², J. Esteban Villarrubia⁴, M.-E. Goebeler⁹, P. Fettes¹³, K. Klar¹³, E. Leo¹⁴, ¹Clinica Universidad de Navarra, Pamplona, Spain, ²CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain, ³Next Oncology, IOB - Hospital Quironsalud Barcelona, Barcelona, Spain, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Universitätsspital Zürich - Klinik für Dermatologie, Zurich, Switzerland, ⁶Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁷ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain, ⁸University Hospital Basel, Basel, Switzerland, ⁹University Clinic Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM), Wuerzburg, Germany, ¹⁰Universitätsklinikum Essen, Essen, Germany, ¹¹Vall d'Hebron University Hospital, Barcelona, Spain, ¹²USZ - University Hospital Zürich, Zurich, Switzerland, ¹³Catalym GmbH, Planegg-Martinsried, Germany, ¹⁴Catalym, Martinsried, Germany

14:25 - 14:35 **LBA2 - First-line (1L) durvalumab plus platinum-etoposide for patients with extensive-stage SCLC (ES-SCLC): Primary results from the Phase 3b LUMINANCE study**

Niels Reinmuth, Asklepios-Fachklinikum, Gauting, Germany

14:35 - 14:45 **LBA3 - Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line metastatic (m) NSCLC: 5-year overall survival (OS) update from the POSEIDON study**

Solange Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

14:45 - 15:00 **Invited Discussant 1180, LBA2 and LBA 3**

Rolf Stahel, Bern, Switzerland

15:00 - 15:10 **640 - Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic nonsquamous non-small cell lung cancer (NSCLC): phase 3 LEAP-006 study**

Roy S. Herbst¹, B.C. Cho², C. Zhou³, M. Burotto⁴, M. Cobo Dols⁵, M.A.N. Sendur⁶, V. Moiseyenko⁷, B. Zurawski⁸, I. Casarini⁹, M. Nishio¹⁰, R. Hui¹¹, E. Pons-Tostivint¹², J. Dudnik¹³, S. Ahmed¹⁴, C. Okpara¹⁵, L. Yin¹⁶, Y. Luo¹⁶, N. Bhagwati¹⁶, D. Rodriguez Abreu¹⁷, ¹Yale University School of Medicine, New heaven, United States of America, ²Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of, ³Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, ⁴Bradford Hill-Clinical Center, Recoleta, Chile, ⁵Hospital Regional Universitario Málaga Carlos Haya, Malaga, Spain, ⁶Ankara Yildirim Beyazit Universty - Faculty of Medicine, Ankara, Turkey, ⁷St. Petersburg Clinical Center of Specialized Medical Care, Saint-Petersburg, Russian Federation, ⁸Prof. Franciszek Lukaszczyk Oncology Centre, Bydgoszcz, Poland, ⁹Hospital Bernardo Houssay, Mar del Plata, Argentina, ¹⁰The Cancer Institute Hospital of JFCR, Koto-ku, Japan, ¹¹Westmead Hospital, Westmead, Australia, ¹²CHU du Nantes - Hôtel-Dieu, Nantes, Cedex, France, ¹³Soroka University Medical Center, Beer Sheva, Israel, ¹⁴University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, ¹⁵Eisai Ltd., Hatfield, United Kingdom, ¹⁶Merck & Co., Inc., Rahway,

United States of America, ¹⁷Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, Spain

15:10 - 15:20

650 - Phase 3 LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy

Natasha Leigh¹, L. Paz-Ares², D. Rodriguez Abreu³, R. Hui⁴, S. Baka⁵, F. Bigot⁶, M. Nishio⁷, A. Smolin⁸, S. Ahmed⁹, A. Schoenfeld¹⁰, S. Daher¹¹, D. Cortinovis¹², V. Di Noia¹³, H. Linardou¹⁴, J. Gainor¹⁵, C. Okpara¹⁶, X. Deng¹⁷, D. Kush¹⁷, A. Song¹⁷, B.C. Cho¹⁸, ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, Canada, ²Hospital Universitario 12 de Octubre, Madrid, Spain, ³Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, Spain, ⁴Westmead Hospital, Westmead, Australia, ⁵European Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece, ⁶Institut de Cancérologie de l'Ouest, Angers, France, ⁷The Cancer Institute Hospital of JFCR, Koto-ku, Japan, ⁸N.N. Burdenko Main Military Clinical Hospital-Ministry of Defence of Russian Federation, Moscow, Russian Federation, ⁹University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, ¹⁰Memorial Sloan Kettering Cancer Center, New York, United States of America, ¹¹Rambam Cancer Division, Haifa, Israel, ¹²Ospedale San Gerardo - ASST Monza, Monza, Italy, ¹³IRCCS Regina Elena National Cancer Institute, Rome, Italy, ¹⁴Metropolitan Hospital, Athens, Greece, ¹⁵MGH - Massachusetts General Hospital, Boston, United States of America, ¹⁶Eisai Ltd., Hatfield, United Kingdom, ¹⁷Merck & Co., Inc., Rahway, United States of America, ¹⁸Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of

15:20 - 15:35

Invited Discussant 640 and 650

Jarushka Naidoo, Beaumont Hospital, Dublin, Ireland

15:35 - 15:45

Q&A

All Speakers, Geneva, Switzerland

14:15 - 15:45	Type: Educational session Title: The future of CNS tumors: Learning from failures and driven by biology Moderation: Christel Herold-Mende, Germany; Hideho Okada, United States of America	Room C
14:15 - 14:35	Immune landscapes of primary and secondary CNS tumors <u>Johanna Joyce</u> , Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Lausanne, Switzerland	
14:35 - 14:55	Checkpoint blockade and CNS tumour microenvironment <u>Bart Neyns</u> , Vrije Universiteit Brussel - Faculty of Medicine & Pharmacy, Brussels, Belgium	
14:55 - 15:15	Immunology and immunotherapy of meningioma <u>Christel Herold-Mende</u> , IPMB, University of Heidelberg, Heidelberg, Germany	
15:15 - 15:35	T cell-based immunotherapy for malignant glioma <u>Hideho Okada</u> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America	
15:35 - 15:45	Q&A and discussion <u>All Speakers</u> , Geneva, Switzerland	
16:15 - 17:15	Type: Controversy session Title: Cell therapy vs bispecific antibodies Moderation: E.G. Elisabeth de Vries, Netherlands	Room A
16:15 - 16:25	Introduction and first vote <u>E.G. Elisabeth De Vries</u> , UMCG - University Medical Center Groningen, Groningen, Netherlands	
16:25 - 16:45	Bispecific antibodies <u>Martin Hutchings</u> , Rigshospitalet, Copenhagen, Denmark	
16:45 - 17:05	Cell therapy <u>Claire Roddie</u> , University College London, London, United Kingdom	
17:05 - 17:15	Second vote and conclusions <u>E.G. Elisabeth De Vries</u> , UMCG - University Medical Center Groningen, Groningen, Netherlands	

16:15 - 17:45	Type: Educational session Title: Anti-cancer pathogen-derived therapies Moderation: Maria Rescigno, Italy; Florencia McAllister, United States of America	Room B
16:15 - 16:35	Mechanisms employed by the tumour microbiome to mediate responses to immunotherapy <u>Florencia Mcallister</u> , The M.D. Anderson Cancer Center, Houston, United States of America	
16:35 - 16:55	Dressing up viruses to fool cancer: Personalised oncolytic vaccine for solid tumours <u>Vincenzo Cerullo</u> , University of Helsinki, Helsinki, Finland	
16:55 - 17:15	Microbiota metabolites to improve immunotherapy <u>Maria Rescigno</u> , Humanitas University, Milan, Italy	
17:15 - 17:35	Humoral immunity against specific bacterial strains is associated with immunotherapy efficacy <u>Safae Terrisse</u> , Hopital Saint Louis AP-HP, Paris, France	
17:35 - 17:45	Q&A and discussion <u>All Speakers</u> , Geneva, Switzerland	
16:15 - 17:45	Type: Educational session Title: The future of immunotherapy in thoracic oncology Moderation: Jarushka Naidoo, Ireland; Tina Cascone, United States of America	Room C
16:15 - 16:35	Immunotherapy combinations in early stage NSCLC <u>Tina Cascone</u> , The University of Texas M. D. Anderson Cancer Center, Houston, United States of America	
16:35 - 16:55	Immunotherapy plus targeted therapy combinations: Promises and pitfalls <u>Jarushka Naidoo</u> , Beaumont Hospital, Dublin, Ireland	
16:55 - 17:15	Next-generation biomarkers of immunotherapy in NSCLC <u>Alessandra Curioni-Fontecedro</u> , Cantonal Hospital Fribourg, Fribourg, Switzerland	
17:15 - 17:35	The microbiome and immunotherapy in NSCLC <u>Lisa Derosa</u> , Institut Gustave Roussy, Villejuif, France	
17:35 - 17:45	Q&A and discussion <u>All Speakers</u> , Geneva, Switzerland	

07.12.2023

08:30 - 10:00 **Type: Educational session** **Room A**
Title: Novel clinical and translational insights in melanoma
 Moderation: Anna Di Giacomo, Italy; Benoit Rousseau, United States of America

08:30 - 08:50 **Peptidomics**
Bernard A. Fox, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, United States of America

08:50 - 09:10 **Neoadjuvant immunotherapy**
Christian Blank, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

09:10 - 09:30 **New target in I-O based combination in melanoma**
Anna Di Giacomo, AOU Senese - Santa Maria delle Scotte, Siena, Italy

09:30 - 09:50 **Adoptive cell transfer: Challenges and future directions**
Inge Marie Svane, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark

09:50 - 10:00 **Q&A and discussion**
All Speakers, Geneva, Switzerland

08:30 - 10:00 **Type: Educational session** **Room B**
Title: Cell therapies
 Moderation: George Coukos, Switzerland; Marion Alcantara, France

08:30 - 08:50 **TIL therapy in melanoma**
John Haanen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

08:50 - 09:10 **Next generation TIL therapies**
George Coukos, UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, Switzerland

09:10 - 09:30 **CAR T-cells for haematological malignancies: The Barcelona experience**
Manuel Juan Otero, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain

09:30 - 09:50 **Improving the cells for CAR T-cell therapy**
Marion Alcantara, Institut Curie, Paris, France

09:50 - 10:00 **Q&A and discussion**
All Speakers, Geneva, Switzerland

08:30 - 09:50

Type: Abstract session
Title: Mini Oral session

Room C

Moderation: Eliane Piaggio, France; Martin Wermke, Germany; Stephane Champiat, France

- 08:30 - 08:35 **50MO - Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma**
David König¹, A. Chirindel², M. Sandholzer³, A. Zingg³, R. Ritschard³, H. Thut³, K. Glatz⁴, E. Kappos¹, C. Kettelhack², D. Lardinois¹, J. Passweg², A. Buser², A. Holbro², L. Jeker², N. Khanna², M. Matter⁴, B. Kasenda¹, N. Rodrigues Mantuano³, A. Zippelius¹, H. Läubli¹, ¹University Hospital Basel, Basel, Switzerland, ²Universitätsspital Basel, Basel, Switzerland, ³University of Basel - Department of Biomedicine, Basel, Switzerland, ⁴University Hospital Basel - Institute of Pathology and Medical Genetics, Basel, Switzerland
- 08:35 - 08:40 **66MO - Early complete metabolic response predicts long-term efficacy after adoptive cell therapy using tumor-infiltrating lymphocytes**
Troels Borch¹, R. Andersen², H. Hendel², E. Ellebæk³, ¹Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark, ²Herlev and Gentofte Hospital, Herlev, Denmark, ³Department of Oncology, Herlev Hospital, Copenhagen University, Herlev, Denmark
- 08:40 - 08:55 **Invited Discussant 50MO and 66MO**
Martin Wermke, Dresden University, Dresden, Germany
- 08:55 - 09:00 **163MO - Single-cell T cell dynamics induced by neoadjuvant nivolumab +/- ipilimumab in early triple negative breast cancer with tumor-infiltrating lymphocytes (BELLINI trial)**
Olga Isaeva¹, I. Nederlof¹, M. De Graaf¹, B. Boeckx², J. Traets¹, I. Mandjes¹, K. Van De Vijver³, M. Chelushkin¹, C. Drukker¹, M. Dongen¹, G. Sonke¹, S. Linn¹, C. Blank¹, K. De Visser¹, R. Salgado⁴, L. Wessels⁵, T. Schumacher¹, H. Horlings¹, D. Lambrechts², M. Kok¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, ²KU Leuven, Leuven, Belgium, ³UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium, ⁴GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, Belgium, ⁵Netherlands Cancer Institute, Amsterdam, Netherlands
- 09:00 - 09:05 **67MO - Neoadjuvant and Adjuvant Toripalimab in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial**
Haiqiang Mai¹, S.-L. Liu², J.H. Yang², D.X. Wen², S.-S. Guo², L. Liu², M.-J. Luo², Y.-J. Liang², X.-S. Sun², X.-Y. Li², L. Donghua², J.-B. Li², P. Wang², L. Guo², H.-Y. Mo², R. Sun², C. Zhao², R.-H. Xu², Q.Y. Chen², L.Q. Tang², ¹Sun Yat-sen University Cancer Center, Guangzhou, China, ²Sun Yat-sen University Cancer Center, Guangzhou, China
- 09:05 - 09:20 **Invited Discussant 163MO**
Eliane Piaggio, Institut Curie, Paris, France
- 09:20 - 09:25 **LBA4 - Low-dose stereotactic body radiotherapy prior to pre-operative**

cemiplimab for patients with resectable hepatocellular carcinoma

Thomas Marron, Icahn School of Medicine at Mount Sinai, New York, United States of America

09:25 - 09:30 **120MO - Adjuvant Pembrolizumab versus Placebo for Early-Stage NSCLC After Resection and Optional Chemotherapy: Updated Results From PEARLS/KEYNOTE-091**

Benjamin Besse¹, L. Havel², S. Peters³, S. Marreaud⁴, N. Jha⁴, K. Oselin⁵, E. Esteban Gonzalez⁶, M.D. Isla Casado⁷, A. Martinez-Marti⁸, M. Faehling⁹, J.-S. Lee¹⁰, Y. Luo¹¹, S. Keller¹², U. Dafni¹³, M. Mauer⁴, R. Stahel¹⁴, M. O'Brien¹⁵, M. Tsuboi¹⁶, L. Paz-Ares¹⁷,
¹Institut Gustave Roussy, Villejuif, France, ²Charles University - First Faculty of Medicine, Prague, Czech Republic, ³CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁴EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, Belgium, ⁵North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, Estonia, ⁶Hospital Universitario Central de Asturias, Oviedo, Spain, ⁷Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Klinikum Esslingen, Esslingen am Neckar, Germany, ¹⁰Seoul National University Bundang Hospital, Seongnam, Korea, Republic of, ¹¹Merck & Co., Inc., Rahway, United States of America, ¹²Merck & Co, Rahway, United States of America, ¹³National and Kapodistrian University of Athens, Athens, Greece, ¹⁴Bern, Switzerland, ¹⁵The Royal Marsden Hospital - Chelsea, London, United Kingdom, ¹⁶National Cancer Center Hospital East, Kashiwa, Japan, ¹⁷Hospital Universitario 12 de Octubre, Madrid, Spain

09:30 - 09:45 **Invited Discussant 67MO, LBA4 and 120MO**

Stephane Champiat, Institut Gustave Roussy, Villejuif, France

10:30 - 12:00 **Type: Educational session** **Room A**
Title: Head and neck cancer
 Moderation: Amanda Psyrris, Greece; Kevin Harrington, United Kingdom

10:30 - 10:50 **Immune evasion in HPV-negative head and neck squamous cell carcinoma (HNSCC)**
Teresa Davoli, NYU School of Medicine, New York, United States of America

10:50 - 11:10 **Preclinical data to inform combinatorial radiation: Immunotherapy clinical design in locally advanced disease**
Lisa Licitra, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

11:10 - 11:30 **Revisiting neoadjuvant therapy in the immunotherapy era**
Amanda Psyrris, Attikon University Hospital, Athens, Greece

11:30 - 11:50 **Combination therapy: Using novel approaches to identify novel biomarkers, inform patient selection and design trials**
Kevin Harrington, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, United Kingdom

11:50 - 12:00 **Q&A and discussion**
All Speakers, Geneva, Switzerland

10:30 - 12:00 **Type: Educational session** **Room B**
Title: Cancer vaccines
 Moderation: Joshua Brody, United States of America; Alessandra Curioni-Fontecedro, Switzerland

10:30 - 10:55 **Cell-based vaccination**
Joshua Brody, Mount Sinai Hospital, New York City, United States of America

10:55 - 11:20 **Neo-antigen cancer vaccination in TMB-low tumours**
Stephen Schoenberger, La Jolla Institute for Immunology, La Jolla, United States of America

11:20 - 11:45 **Cancer vaccination in hepatocellular carcinoma (HCC)**
Luigi Buonaguro, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, Italy

11:45 - 12:00 **Q&A and discussion**
All Speakers, Geneva, Switzerland

10:30 - 12:00 **Type: Educational session** **Room C**
Title: Mesothelioma
 Moderation: Astero Klampatsa, United Kingdom; Rolf Stahel, Switzerland

10:30 - 10:50 **Immune biomarker discovery and neoantigen identification in mesothelioma**

Jenette Creaney, University of Western Australia, Perth, Australia

10:50 - 11:10 **Overview of mesothelioma frontline treatments**

Solange Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

11:10 - 11:30 **I-O combinations in later line therapy for mesothelioma**

Sjaak Burgers, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

11:30 - 11:50 **The potential of CAR T-cell therapy in mesothelioma**

Astero Klampatsa, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom

11:50 - 12:00 **Q&A and discussion**

All Speakers, Geneva, Switzerland

12:00 - 13:00 **Type: Poster Display** **Foyer mezzanine**
Title: Poster Display

12:00 - 12:00 **1P - Integrated Data Analysis within IMMUCan Identifies Prognostic Features of Early NSCLC**

Daniel Schulz¹, M. Morfouace², N. Eling³, M. Daniel⁴, S. Déglise⁴, B. Palau Fernandez⁴, J. Windhager⁴, S. Rusakiewicz⁵, S. Tissot⁵, T. Trefzer⁶, J. Merlevede⁷, F. Marzetta⁸, R. Liechti⁸, H. Hong⁹, T. Cufer¹⁰, P. Bironzo¹¹, A.-M. Dingemans¹², B. Besse¹³, B. Bodenmiller⁴, ¹UZH - University of Zurich - Irchel Campus, Zurich, Switzerland, ²Merck KGaA - Headquarters Merck Group, Darmstadt, Germany, ³UZH - University of Zurich - Competence Center Personalized Medicine (CC-PM), Zurich, Switzerland, ⁴University of Zurich, Zurich, Switzerland, ⁵Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, Switzerland, ⁶Bayer AG, Berlin, Germany, ⁷Institut Curie; INSERM U900; Mines ParisTech, Paris, France, ⁸SIB - Swiss Institute of Bioinformatics, Lausanne, Switzerland, ⁹Merck KGaA, Darmstadt, Germany, ¹⁰University of Ljubljana - Faculty of Medicine, Ljubljana, Slovenia, ¹¹Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Italy, ¹²Erasmus MC - University Medical Center, Rotterdam, Netherlands, ¹³Institut Gustave Roussy, Villejuif, France

12:00 - 12:00 **3P - Exploratory efficacy analysis by smoking status in PD-L1 high patients in the phase III, non-small cell lung cancer (NSCLC) IMpower110 study**

Luis Paz-Ares¹, M.R. García-Campelo², M.D. Isla Casado³, E. Carcereny⁴, D. Rodriguez Abreu⁵, J.J. Garcia Gonzalez⁶, D. Parente⁷, N. Gonzalez Mancha⁷, E. Vilas⁸, P. Ruiz Gracia⁸, A. Greco⁹, D. Spigel¹⁰, F. De Marinis¹¹, J. Jassem¹², ¹Hospital Universitario ²

de Octubre, Madrid, Spain, ²CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ³Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain, ⁴ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, Spain, ⁵Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, Spain, ⁶CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, Spain, ⁷Roche Farma Spain, Madrid, Spain, ⁸Roche Farma S.A., Madrid, Spain, ⁹F. Hoffmann-La Roche AG, Basel, Switzerland, ¹⁰Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America, ¹¹IEO - Istituto Europeo di Oncologia, Milan, Italy, ¹²Medical University of Gdansk, Gdansk, Poland

- 12:00 - 12:00 **4P - Immune exoproteome, soluble proteome and immune-related gene expression profiles of anti-PD-1 therapy in stage IIIB/IV Non-Small Cell Lung Cancer: relevance of immunosuppressive factors**
- Paulo Santos¹, L.M. Sousa², J.S. Almeida², F. Barata³, A.M. Figueiredo³, ¹Faculty of Medicine, University of Coimbra, Coimbra, Portugal, ²University of Coimbra, Coimbra, Portugal, ³CHUC - Centro Hospitalar e Universitario de Coimbra - Hospital Geral, Coimbra, Portugal
- 12:00 - 12:00 **5P - Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC**
- Giulia Mazzaschi¹, G. Monica¹, M. Pluchino¹, B. Lorusso¹, S. D'Agnelli¹, M. Verzè², R. Minari³, F. Perrone¹, P. Bordi¹, A. Leonetti¹, F. Quaini¹, N. Sverzellati², M. Tiseo⁴, ¹University of Parma, Parma, Italy, ²Ospedal Maggiore di Parma, Parma, Italy, ³University Hospital of Parma, Parma, Italy, ⁴Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
- 12:00 - 12:00 **6P - CD161+CD127+CD8+ T cells as a critical predictor of the efficacy of anti-PD-1 immunotherapy in diabetic patients with non-small cell lung cancer**
- Jingjing Qu¹, Y. Li², L. Chen², Q. Shen¹, J. Zhou³, ¹The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China, ²The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, China, ³The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- 12:00 - 12:00 **7P - A T-cell-derived circulating DNA as a biomarker for response to anti-PD(L)1 immunotherapy in advanced stage non-small cell lung cancer**
- Nuthchaya Mejun¹, M. Prasanpanich², N. Leelayuwatanakul², P. Ouwongprayoon², C. Vinayanuwattikun², N. Hirankarn², ¹Chulalongkorn University - Faculty of Medicine, Bangkok, Thailand, ²Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand
- 12:00 - 12:00 **9P - Primary NSCLC patient-derived microtumors (PMTs) for clinical-relevant prediction of immunotherapy efficacy**
- Fabienne Nocera¹, F. Mildner¹, J. Kelm², M. Freitas², K. Nikitina², S. Manser², S. Sopper¹, G. Gamerith³, A. Seeber⁴, A. Amann³, ¹Innsbruck Medical University, Innsbruck, Austria, ²PreComb Therapeutics AG, Hombrechtikon, Switzerland, ³Medical University of Innsbruck, Innsbruck, Austria, ⁴Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, Austria

- 12:00 - 12:00 **10P - Lung Immune Prognostic Index (LIPI) Predicts Response to Immune Checkpoint Inhibitors in NSCLC Patients**
Carlos Izquierdo Tolosa¹, M. Ramos Ramirez², L. Cabrera Miranda², E. Caballe Perez², A. Regino², N. Lozano-Vazquez², O.G. Arrieta Rodriguez², ¹Hospital Medica Sur Tlalpan, Ciudad de Mexico, Mexico, ²INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico
- 12:00 - 12:00 **11P - Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer**
Liang Zheng¹, A. Xiong², W. Nie², X. Zhang², ¹Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China, ²Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 12:00 - 12:00 **12P - Spatially preserved multi-region transcriptomic subtyping and biomarkers associated with long-term benefit with chemoimmunotherapy in extensive-stage small cell lung cancer (ES-SCLC)**
Melina Peressini Álvarez¹, C. Martí Cubells², V. Gutierrez Calderon³, B. Massuti Sureda⁴, M. Majem⁵, M.R. García-Campelo⁶, P. Diz Tain⁷, M.D. Isla Casado⁸, A. Moreno Paul⁹, F.J. Garcia Navalon¹⁰, M. Molero¹¹, V. Adradas¹¹, E. Conde Gallego¹, L. Paz-Ares¹, J. Zugazagoitia¹, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Hospital Universitari Sant Joan de Reus, Reus, Spain, ³Hospital Regional Universitario Málaga Carlos Haya, Malaga, Spain, ⁴Hospital General Universitario de Alicante, Alicante, Spain, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁷Complejo Asistencial Universitario de León - Hospital de León, León, Spain, ⁸Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain, ⁹Hospital Galdakao - Usansolo, Galdakao, Spain, ¹⁰Hospital Son Llatzer, Palma de Mallorca, Spain, ¹¹Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre, Madrid, Spain
- 12:00 - 12:00 **13P - Efficacy and biomarker exploration of Anlotinib plus Penpulimab for extensive stage Small cell lung cancer who failed from previous Platinum-Based Chemotherapy: Result from A phase II perspective trials**
Yongchang Zhang¹, Z. Wu², Q. Chen³, C. Zhou¹, M. Xiao⁴, C. Wang⁴, L. Zeng¹, W. Jiang¹, B. Zhang⁵, J. Liang⁵, L. Liu¹, H. Yang¹, Y. Xiong¹, Z. Wang¹, F. Zeng¹, C. Zhou⁶, Y. Feng⁷, N. Yang¹, ¹Hunan Provincial Cancer Hospital, Changsha, China, ²The First People's Hospital of Changde, Changde, China, ³Fuzhou Pulmonary Hospital of Fujian, Fuzhou, China, ⁴Hunan Traditional Chinese Medical College No.1 Affiliated Hospital, Zhuzhou, China, ⁵Hunan Yiyang Central Hospital, Yiyang, China, ⁶State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, China, ⁷The Xiangtan Central Hospital, Xiangtan, China
- 12:00 - 12:00 **14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response**
Juan Luis Melero¹, B. Colom-Sanmartí¹, A. Mendizabal-Sasieta¹, U. Perron¹, M. Grzelak¹, D. Pravdyvets¹, M. Soto¹, J.C. Nieto², S. Vidal³, S. Tejpar⁴, N. Borchering¹, E. Planas

Rigol¹, H. Heyn², ¹Omniscop, Barcelona, Spain, ²Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴KU Leuven, Leuven, Belgium

- 12:00 - 12:00 **16P - Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma**
Yongshun Chen, Y. Tian, W. Zhang, J. Wang, W. Shi, H. Qiu, Z. Huang, Y. Gong, Y. Wu, S. Ke, Renmin Hospital of Wuhan University, Wuhan, China
- 12:00 - 12:00 **17P - Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis**
Gang Che¹, J. Liu², ¹The First Affiliated Hospital of Zhejiang University, Hangzhou, China, ²The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China
- 12:00 - 12:00 **18P - Association of DNA methylation profiles with pathologic complete response in early triple negative breast cancer patients receiving neoadjuvant chemoimmunotherapy**
Angelika Starzer¹, E. Tomasich², G. Heller², L. Gottmann³, J. Berger³, M. Korpan³, C. Englisch³, M. Kleinberger⁴, M. Preusser², R. Bartsch³, A.S. Berghoff², ¹Medizinische Universitaet Wien, Vienna, Austria, ²Universitätskliniken der MedUni Wien - AKH Wien, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴MedUni Wien - Medical University of Vienna, Vienna, Austria
- 12:00 - 12:00 **19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial**
Denis Zoë¹, P. Kristanto², X. Catteau³, D. Vincent², V. Debien², E. Agostinetto², J. Stagg⁴, R. Salgado⁵, D. Larsimont², C. Sotiriou⁶, F. Rothé², L. Buisseret⁶, ¹ULB - Université Libre de Bruxelles - Faculté de Médecine, Brussels, Belgium, ²Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium, ³Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium, ⁴University of Montreal Health Center, Montreal, Canada, ⁵GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, Belgium, ⁶Institute Jules Bordet, Brussels, Belgium
- 12:00 - 12:00 **20P - Deciphering tumor microenvironment heterogeneity between primary tumor and metastases in high grade serous ovarian cancer (HGSC) to predict response to immunotherapy (IT): analyses from the NeoPembrOv/GINECO phase II trial**
Laetitia Collet¹, M. Ardin², D. Venet¹, J. Berthet², I. Treilleux³, M. Leheurteur⁴, J. Meunier⁵, L. Bengrine Lefevre⁶, M. Martinez⁷, F. Priou⁸, F. Selle⁹, P.-A. Just¹⁰, G. Bataillon¹¹, F. Rothé¹², C. Sotiriou¹, B. Dubois², C. Caux¹³, I. Ray-Coquard³, O. Le Saux³, ¹Institute Jules Bordet, Brussels, Belgium, ²CRCL - Centre de recherche en cancerologie de Lyon, Lyon, Cedex, France, ³Centre Léon Bérard, Lyon, France, ⁴Centre Henri Becquerel, Rouen, France, ⁵CHR - Centre Hospitalier Régional d'Orléans - La Source, Orleans, France, ⁶Centre Georges-François Leclerc (Dijon), Dijon, France, ⁷Clinique Pasteur, Toulouse, France, ⁸CHD Vendée - Hopital Les Oudairies, La Roche-sur-Yon, France, ⁹Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France, ¹⁰AP-HM -

CHU La Timone Enfants, Marseille, France, ¹¹IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France, ¹²Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium, ¹³Centre de recherche en cancérologie de Lyon (CRCL), Lyon, France

12:00 - 12:00 **21P - Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE).**

Alexandre Bertucci¹, P. Maby², P. Rochigneux¹, F. Legrand³, C. Cropet⁴, J.-S. Frenel⁵, C. Le Tourneau⁶, A. Hervieu⁷, E. Coquan⁸, T. De La Motte Rouge⁹, E. Saada¹⁰, P. Lavaud¹¹, A. Ben-Amara², M.-S. Rouvière², P. Grassi¹, L. Gorvel², A. Goncalves¹, D. Olive², A.-S. Chrétien², ¹Institute Paoli Calmettes, Marseille, France, ²CRCM - Centre de Recherche en Cancérologie de Marseille, Marseille, Cedex, France, ³Unicancer, Paris, Cedex, France, ⁴Centre Léon Bérard, Lyon, France, ⁵ICO Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France, ⁶Institut Curie, Paris, France, ⁷Centre Georges-François Leclerc (Dijon), Dijon, France, ⁸Centre Francois Baclesse, Caen, Cedex, France, ⁹Centre Eugene - Marquis, Rennes, France, ¹⁰Centre Anticancer Antoine Lacassagne, Nice, France, ¹¹Institut Gustave Roussy, Villejuif, Cedex, France

12:00 - 12:00 **22P - Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced/ recurrent endometrial cancer treated with Dostarlimab.**

Maria Kfoury¹, F. Pesce², M. Provansal Gross², E. Charafe², L. Gorvel³, F. Rousseau², M.A. Cappiello², R. Sabatier², ¹IPC - Institut Paoli-Calmettes, Marseille, France, ²IPC - Institut Paoli-Calmettes, Marseille, Cedex, France, ³CRCM - Centre de Recherche en Cancérologie de Marseille, Marseille, Cedex, France

12:00 - 12:00 **23P - Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma**

Ronan Flippot¹, M. Teixeira², E. Roblin², L. Carril Ajuria¹, M. Naigeon², L. Rainho¹, L. Cassard², F.-X. Danlos², B. Escudier¹, L. Albiges², N. Chaput-Gras², ¹Institut Gustave Roussy, Villejuif, France, ²Institut Gustave Roussy, Villejuif, Cedex, France

12:00 - 12:00 **24P - Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis**

Matteo Rosellini¹, V. Mollica², S. Coluccelli³, F. Giunchi², C. Ricci⁴, A. Marchetti², E. Tassinari², M. Fiorentino⁴, D. De Biase⁵, F. Massari², ¹AOU Policlinico S. Orsola-Malpighi, Bologna, Italy, ²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ³University of Bologna - Dipartimento di Scienze Mediche e Chirurgiche, Bologna, Italy, ⁴Maggiore Hospital-AUSL Bologna, Bologna, Italy, ⁵University of Bologna - Alma Mater Studiorum, Bologna, Italy

12:00 - 12:00 **25P - Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation**

Gregor Duwe¹, L. Müller¹, C. Ruckes¹, N. Fischer¹, L. Frey¹, J. Börner¹, N. Rölz¹, M. Haack¹, P. Sparwasser¹, T. Jorg¹, C. Neumann², I. Tsaour¹, T. Höfner³, A. Haferkamp¹, F.

Hahn¹, R. Mager¹, M. Brandt¹, ¹Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany, ²Charité - Universitätsmedizin Berlin, Berlin, Germany, ³Ordensklinikum Linz Elisabethinen, Linz, Austria

- 12:00 - 12:00 **26P - Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the Phase 2 ARCADIA trial)**
- Veronica Huber¹, A. Mereu¹, L. Lalli¹, J. Salsetta¹, C. Banfi¹, P. Squarcina¹, F. Sgambelluri¹, R. Mortarini¹, M. Stellato¹, D. Raggi², V. Guadalupi³, M. Claps⁴, W. Ferrari Bravo¹, G. Calareso¹, A. Alessi¹, A. Anichini¹, G. Procopio¹, A. Necchi², L. Rivoltini³, P. Giannatempo¹, ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy, ²IRCCS Ospedale San Raffaele, Milan, Italy, ³Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy
- 12:00 - 12:00 **27P - Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA): preliminary analysis from the Phase 2 ARCADIA trial.**
- Francesco Sgambelluri¹, P. Giannatempo¹, M. Stellato¹, V. Guadalupi², D. Raggi³, A. Bottiglieri¹, M. Claps⁴, W. Ferrari Bravo¹, S. Oldani¹, M. Zimatore¹, G. Calareso¹, A. Alessi¹, L. Cattaneo¹, E. Verzoni¹, F.G.M. De Braud¹, G. Procopio¹, A. Necchi³, A. Anichini¹, R. Mortarini¹, ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy, ²Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy, ³IRCCS Ospedale San Raffaele, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy
- 12:00 - 12:00 **28P - 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms**
- Frank Stenner-Liewen¹, M. Galsky², D. Bajorin³, J. Witjes⁴, J. Gschwend⁵, Y. Tomita⁶, F. Nasroulah⁷, M. Askelson⁸, B. Perez Valderrama⁹, M.-O. Grimm¹⁰, L. Appleman¹¹, G. Gravis¹², A. Necchi¹³, D. Ye¹⁴, J. David¹⁵, ¹Universitätsspital Basel, Basel, Switzerland, ²Icahn School of Medicine at Mount Sinai, New York, United States of America, ³MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America, ⁴Radboud University Medical Center, Nijmegen, Nijmegen, Netherlands, ⁵Klinikum Rechts der Isar - Technische Universität München, Munich, Germany, ⁶Niigata University Medical and Dental Hospital, Niigata, Japan, ⁷Bristol Myers Squibb, San Francisco, United States of America, ⁸BMS - Bristol-Myers Squibb, Cambridge, United States of America, ⁹Hospital Universitario Virgen del Rocío, Seville, Spain, ¹⁰Universitätsklinikum Jena - Klinik für Innere Medizin II, Jena, Germany, ¹¹University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, United States of America, ¹²IPC - Institut Paoli-Calmettes, Marseille, Cedex, France, ¹³IRCCS Ospedale San Raffaele, Milan, Italy, ¹⁴Fudan University Shanghai Cancer Center, Shanghai, China, ¹⁵Bristol Myers Squibb - Cambridge, Cambridge, United States of America
- 12:00 - 12:00 **29P - The Impact of Body Mass Index on Survival Endpoints among Patients with Metastatic Urothelial Carcinoma Undergoing Treatment with Immune Checkpoint Inhibitors: A Real-World Multicenter Analysis**
- Yu-Li Su, S.-Y. Huang, C.-T. Lin, H.L. Luo, Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan

- 12:00 - 12:00 **30P - CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma**
- Sangeeta Bishesar¹, M. Van Der Kamp², J. De Vries², L. Slagter-Menkema², E. Schuurin², G. Lunter², G. Halmos², B. Van Der Vegt², ¹The University Medical Center - UMCG, Groningen, Netherlands, ²UMCG - University Medical Center Groningen, Groningen, Netherlands
- 12:00 - 12:00 **31P - Characterization of pre-exhausted / exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB).**
- Ioannis Kotsantis¹, P. Economopoulou¹, S. Doumas², A. Spathis¹, M. Anastasiou¹, M. Moutafi¹, A. Kyriazoglou¹, M. Kirkasiadou¹, N. Gavrielatou¹, I. Pateras¹, I. Panayiotides¹, P. Foukas¹, A. Psyrris³, ¹Attikon University Hospital, Haidari, Greece, ²William Harvey Hospital - East Kent Hospitals University NHS Foundation Trust, Ashford, United Kingdom, ³Attikon University Hospital, Athens, Greece
- 12:00 - 12:00 **32P - Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor**
- Natasha Honoré¹, A. Van Der Elst², A. Dietz³, C. Van Marcke De Lummen³, R. Helaers⁴, A. Mendola⁵, H. Dahou⁵, E. Marbaix³, R. Poncin⁶, E. Seront⁷, S. Schmitz³, N. Limaye⁴, R. Galot³, J.-P. Machiels³, ¹UCLouvain - Pôle de Pharmacologie et Thérapeutique (FATH), Woluwe-Saint-Lambert, Belgium, ²UCLouvain Brussels Woluwe, Brussels, Belgium, ³Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, Belgium, ⁴De Duve Institute UCLouvain, Woluwe-Saint-Lambert, Belgium, ⁵UCLouvain - Université Catholique de Louvain, Woluwe-Saint-Lambert, Belgium, ⁶Clinique Saint-Pierre asbl, Ottignies-Louvain-la-Neuve, Belgium, ⁷Centre Hospitalier Jolimont-Lobbes, Haine-Saint-Paul, Belgium
- 12:00 - 12:00 **33P - Impact of prior treatment on baseline immune biomarkers and nivolumab + relatlimab (NIVO+RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with melanoma from RELATIVITY-020**
- Paolo Ascierto¹, S. Dolfi², M. Nyakas³, I.M. Svane⁴, E. Munoz Couselo⁵, J.J. Grob⁶, C. Gomez-Roca⁷, V. Chiarion Sileni⁸, K. Peltola⁹, J. Larkin¹⁰, I. Melero¹¹, M. Callahan¹², R. Dummer¹³, P. Djidel², D. Warad¹⁴, E. Lipson¹⁵, C. Garnett-Benson¹⁶, ¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, Italy, ²Bristol-Myers Squibb, Princeton, United States of America, ³Oslo University Hospital, Oslo, Norway, ⁴Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark, ⁵Vall d'Hebron Institute of Oncology, Barcelona, Spain, ⁶Aix-Marseille University, Marseille, France, ⁷Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France, ⁸Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy, ⁹HUS Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland, ¹⁰The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom, ¹¹Clinica Universidad de Navarra, Pamplona, Spain, ¹²Memorial Sloan Kettering Cancer Center, New York, United States of America, ¹³USZ - University Hospital Zürich, Zurich, Switzerland, ¹⁴Bristol Myers Squibb, Cambridge, United States of America, ¹⁵Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, United States of America, ¹⁶Bristol

Myers Squibb, Princeton, United States of America

- 12:00 - 12:00 **34P - Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients - assessment of lesion-level response with 18F-FDG PET/CT**
Katja Strasek¹, D. Huff², N. Hribernik³, L. Zurbriggen⁴, A. Doma³, E. Lawrence², A. Studen⁵, V. Ma⁴, V. Fernandes², M. Albertini⁴, K. Zevnik³, K. Škalic³, M. Rebersek³, R. Jeraj², ¹Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, Slovenia, ²University of Wisconsin-Madison, Madison, United States of America, ³Institute of Oncology Ljubljana, Ljubljana, Slovenia, ⁴University of Wisconsin Carbone Cancer Center, Madison, United States of America, ⁵University of Ljubljana, Ljubljana, Slovenia
- 12:00 - 12:00 **35P - Peripheral immunotype classification for monitoring Soft Tissue Sarcoma patients**
Jani Sofia Almeida¹, L.M. Sousa¹, J. Rodrigues², R. Fonseca², V. Alves¹, M. Santos-Rosa¹, P. Tavares³, J.M. Casanova², P. Santos⁴, ¹University of Coimbra, Coimbra, Portugal, ²CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal, ³CHUC - Centro Hospitalar e Universitario de Coimbra - Hospital Geral, Coimbra, Portugal, ⁴Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- 12:00 - 12:00 **36P - Expression of germinal center B cell- and Th17 cell-related transcripts are prognostic of soft-tissue sarcoma patient outcomes**
Giulia Petroni¹, E. Caliman², R. Scanferla², G. Scoccianti², A. Palomba², D.A. Campanacci², L. Antonuzzo², S. Pillozzi¹, ¹UniFI - Università degli Studi di Firenze, Firenze, Italy, ²AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
- 12:00 - 12:00 **38P - Machine learning-based pathomics model to predict the infiltration of Treg and prognosis in IDH-wt GBM**
Shaoli Peng¹, X. Wang², J. Hong², M. Zhang², ¹The First Affiliated Hospital of Fujian Medical University, Fuzhou, China, ²the First Affiliated Hospital of Fujian Medical University, Fuzhou, China
- 12:00 - 12:00 **39P - Patient selection based on hyperprogressive disease risk nearly doubles survival benefit of immune checkpoint blockade: validation of a pan-tumor tissue agnostic combined biomarker approach**
Partha Ray¹, C. Taylor², R. Hussa³, ¹Onsite Healthcare, Lincolnwood, United States of America, ²Keck School of Medicine - University of Southern California USC, Los Angeles, United States of America, ³Onconostic Technologies, Inc., Champaign, United States of America
- 12:00 - 12:00 **37P - Association between blood cell composition and survival outcome in glioma patients: A topic modeling approach**
Sara Hadad, G. Warriar, L. McCoy, J.K. Wiencke, A.M. Molinaro, UCSF - University of California San Francisco, San Francisco, United States of America
- 12:00 - 12:00 **40P - The role of low avidity tumour-specific CD8+ T cells in immunotherapeutic response to anti-PD-1**
Doreen Lau¹, S.L. Hill², D. Arcia-Anaya¹, D.M. Boulanger², E.E. Parkes¹, E. James², T.

Elliott¹, ¹University of Oxford, Oxford, United Kingdom, ²University of Southampton, Southampton, United Kingdom

- 12:00 - 12:00 **41P - Contrasting drivers of response to immunotherapy across solid tumour types: results from analysis of >2500 cases**
Danwen Qian¹, K. Thakkar¹, A. Castro¹, C. Swanton², K. Litchfield¹, ¹UCL Cancer Institute - UCL - London's Global University, London, United Kingdom, ²Francis Crick Institute, London, United Kingdom
- 12:00 - 12:00 **42P - TCCIA: A Comprehensive Resource for Exploring CircRNA in Cancer Immunotherapy**
Jian-Guo Zhou¹, S. Wang², Y. Xiong³, Y. Zhang³, H. Wang⁴, H. Ma⁵, U. Gaip⁶, ¹The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China, ²State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China, ³CSU - Central South University - Xiangya School of Medicine - New Campus, Changsha, China, ⁴UM - University of Macau, Taipa, Macau PRC, ⁵The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, China, ⁶Universität Erlangen-Nürnberg, Nürnberg, Germany
- 12:00 - 12:00 **43P - Immune and tumor cells expression of VISTA in a panel of cancer indications: A strategy to inform selection of patients treated with anti-VISTA**
Pierre Launay¹, A. Pillon¹, R. Bonnet¹, D. Vinet¹, A. Alloy¹, L. Lacastaigneratte¹, C. Welsch¹, C. Larzabal¹, G. Zorza², G. Gueguen Dorbes¹, O. Geneste¹, F. Hofmann¹, M.-O. Roy¹, ¹Pierre Fabre Laboratories, Toulouse, France, ²Pierre Fabre Laboratories, TOULOUSE, France
- 12:00 - 12:00 **44P - Exploratory Analysis of Peripheral Pharmacodynamic (PD) Biomarkers After Sitravatinib (Sitra) and Tislelizumab (TIS) in Advanced Solid Tumors: SAFFRON-103**
Yi-Long Wu¹, B. Gao², J. Goh³, J. Zhao⁴, Z. Ma⁵, J. Cui⁶, X. Yu⁷, D. Huang⁸, D. Day⁹, M. Voskoboynik¹⁰, Q. Chu¹¹, Q. Zhou¹², M. Millward¹³, H. Pan¹⁴, M. Sun¹⁵, Y. Peng¹⁶, M. Liu¹⁷, T. Tian¹⁷, H. Li¹⁶, J. Guo¹⁸, ¹Guangdong Province People's Hospital, Guangzhou, China, ²Blacktown Cancer and Haematology Centre, Sydney, Australia, ³Icon Cancer Foundation, Brisbane, Australia, ⁴Peking University Cancer Hospital and Institute, Beijing, China, ⁵Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, ⁶The First Bethune Hospital of Jilin University, Changchun, China, ⁷Zhejiang Cancer Hospital, Hangzhou, China, ⁸Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, ⁹Monash Health - Monash Medical Centre, Clayton, Australia, ¹⁰Alfred Hospital, Melbourne, Australia, ¹¹Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ¹²Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, ¹³Linear Clinical Research and University of Western Australia, Perth, Australia, ¹⁴Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China, ¹⁵Jinan Central Hospital Affiliated to Shandong University, Jinan, China, ¹⁶BeiGene (Shanghai) Co., Ltd., Shanghai, China, ¹⁷BeiGene (Beijing) Co., Ltd., Beijing, China, ¹⁸Peking University Cancer Hospital & Institute, Beijing, China
- 12:00 - 12:00 **45P - Protein biomarkers associated with organ-specific immune-related toxicity**

and response to management identified by proteome analysis of extracellular vesicles from plasma

Anders Kverneland¹, J. Jörn¹, I. Noringriis¹, R. Jurlander¹, O. Østergaard², J.V. Olsen², I.M. Svane¹, ¹Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark, ²University of Copenhagen, Copenhagen, Denmark

- 12:00 - 12:00 **46P - Immunoprofiling of Peripheral Blood Cells as a Potential Predictor of Immune-Related Toxicity of PD-1 Inhibitors**
Jan Podhorec¹, S. Borilova¹, O. Bilek¹, A. Poprach², I. Kiss¹, L. Zdrzilova Dubska³, P. Grell¹, ¹Masaryk Memorial Cancer Institute, Brno, Czech Republic, ²Faculty of Medicine, Masaryk University, Brno, Czech Republic, ³FN Brno Bohunice - University Hospital Brno, Brno, Czech Republic
- 12:00 - 16:15 **47TiP - A real-world study of multiparametric prediction of the efficacy of immune checkpoint inhibitors in combination with chemotherapy for advanced non-small cell lung cancer**
Zihan Zhou, Y. Song, Z. Song, X. Zhu, S. Han, Southeast University - Dingjiaqiao Campus, Nanjing, China
- 16:15 - 16:15 **51P - Phase 1B (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): preliminary results**
Laura Ridolfi¹, A. Delmonte¹, F. De Rosa¹, I. Azzali¹, G. Gentili¹, M. Petrini¹, E. Pancisi¹, A.M. Granato¹, J. Bulgarelli¹, C. Doglioni², M.A. Burgio¹, M. Ragonesi¹, F. Stella³, P. Cortesi¹, C. Casadei¹, M. Garaffoni¹, D. Barone¹, M. Guidoboni¹, ¹IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, Italy, ²IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Ospedale "Morgagni - Pierantoni" di Forlì, Forlì, Italy
- 16:15 - 16:15 **52P - The dependence of TKI-resistant lung cancer cells on EGFR increases sensitivity to EGFR-CAR NK.**
Sumei Chen, Hangzhou Cancer Hospital, Hangzhou, China
- 16:15 - 16:15 **53P - Integrin- α 6 targeted CAR T-cells in an immunocompetent orthotopic model of pancreatic cancer**
Nicholas Brown¹, L. Cutmore², E. Murray², J. Marshall², ¹St George's Hospital NHS Trust, London, United Kingdom, ²Barts Cancer Institute, London, United Kingdom
- 16:15 - 16:15 **55P - DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex**
Wei Zhang, Y. Wang, X. Tian, D. Ye, Fudan University Shanghai Cancer Center, Shanghai, China
- 16:15 - 16:15 **54P - (Withdrawn)**
- 16:15 - 16:15 **56P - FOXM1D in T cells promotes the transcription of PD-1 by interacting with HCFC1 and regulating the killing of renal cancer cells**

Yue Wang, W. Zhang, T. Feng, X. Tian, K. Chang, D. Ye, Fudan University Shanghai Cancer Center, Shanghai, China

- 16:15 - 16:15 **57P - Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL)**
- Joachim Stoltenborg Granhøj¹, T. Borch¹, M. Rohaan², K. Madsen¹, I. Jedema², C. Nijenhuis², M. Van Zon², B. Nuijen², W. Van Houdt³, L. Rosenkrantz Hölmich⁴, Ö. Met¹, M. Donia⁵, J. Haanen³, I.M. Svane¹, ¹Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark, ²Netherlands Cancer Institute, Amsterdam, Netherlands, ³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, ⁴Herlev Hospital, Herlev, Denmark, ⁵Department of Oncology, Herlev Hospital, Copenhagen University, Herlev, Denmark
- 16:15 - 16:15 **58P - Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers**
- Liangping Li, Guangzhou Overseas Chinese Hospital/The First Affiliated Hospital of Jinan University, Guangzhou, China
- 16:15 - 16:15 **59P - Revolutionizing cell therapy testing by co-culturing 3D patient derived cancer models and circulating immune cells on Organ-on-chip platform**
- Silvia Scaglione¹, E. Palama², M. Aiello², ¹CNR, Genova, Italy, ²React4life Srl, Genova, Italy
- 16:15 - 16:15 **60P - Adaptive NK cells as a therapeutic option for childhood leukaemia**
- Zoya Eskandarian¹, R.T. Hauch², M. Spohn², A.-L. Heitmann², C. Imelmann², K. Rudloff², M. Goos², J. Strauss², S. Schuster², U. Schüller², M. Horstmann², ¹University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ²Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 16:15 - 16:15 **61P - Unlocking the Power of Natural Killer Cells: Precision Selection with Cutting-Edge Microfluidics**
- Neelima Kc, Imperial College London - South Kensington Campus, London, United Kingdom
- 16:15 - 20:30 **63TiP - A phase I study of tumor-infiltrating lymphocytes (TILs) in advanced solid tumors used an optimized regimen: MIZAR trial**
- Qing Xu¹, X. Guo¹, J. Zhang², W. Shen², H. Jin³, C. Zhao⁴, J. Xu⁴, ¹Shanghai Tenth People's Hospital, Shanghai, China, ²Fudan University Shanghai Cancer Center, Shanghai, China, ³Shanghai Juncell Therapeutics Co., Ltd, Shanghai, China, ⁴Chinese PLA General Hospital (301 Military Hospital), Beijing, China
- 20:30 - 20:30 **62P - Solupore® is a novel platform used for the delivery of gene editing tools and modalities, yielding healthier edited primary immune cells with superior function compared with electroporation.**
- Jamie Frankish, Avectas, Maynooth, Ireland

- 20:30 - 20:30 **68P - Real-world (rw) outcomes in patients (pts) with metastatic (m) NSCLC and STK11, KEAP1 and/or KRAS mutations (mut) receiving PD-(L)1-based treatment (tx): CORRELATE**
- Solange Peters¹, R. Salomonsen², F. Skoulidis³, I. Diaz Perez², A. Wang², M. Cooper⁴, S. Liu⁵, ¹CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ²AstraZeneca, Gaithersburg, United States of America, ³The University of Texas MD Anderson Cancer Center, Houston, United States of America, ⁴AstraZeneca, Cambridge, United Kingdom, ⁵Georgetown University, Washington, United States of America
- 20:30 - 20:30 **70P - LIST (Lung Initiative on Sequence Therapy), a real-world study of nivolumab for advanced NSCLC in France: first effectiveness, safety, and IO-rechallenge results**
- Benoît Godbert¹, M. Zysman², E. Gobbini³, C. Decroisette⁴, H. Lena⁵, D. Moro-Sibilot⁶, F. Guisier⁷, T. Egenod⁸, S. Couraud⁹, A. Caraux¹⁰, A. Fleuriet¹⁰, F. Brellier¹¹, N. Girard¹², ¹Hopital Robert Schuman - UNEOS, Vantoux, France, ²University Hospital of Bordeaux, Bordeaux, France, ³Institut Curie, Paris, France, ⁴Léon Bérard Center, Lyon, France, ⁵Hop Pontchaillou, Rennes, France, ⁶University Hospital of Grenoble, La Tronche, France, ⁷University Hospital of Rouen, Rouen, France, ⁸University Hospital of Limoges, Limoges, France, ⁹Lyon Sud Hospital, Hospices Civils de Lyon, Oullins, France, ¹⁰Bristol Myers Squibb, Rueil-Malmaison, France, ¹¹Bristol Myers Squibb Pharmaceuticals Limited, Uxbridge, United Kingdom, ¹²Institut du Thorax Curie Montsouris, Institut Curie and UVSQ, Paris Saclay, Paris/Versailles, France
- 20:30 - 20:30 **72P - Camrelizumab plus apatinib after chemoradiotherapy in unresectable stage III non-small-cell lung cancer?A multi-center, single-arm, phase 2 study**
- Hui Zhouguang¹, Y. Zhai¹, Y. Men¹, W. Zhou², Y. Wu², X. Jiang³, Y. Zhang³, D. Sun⁴, M. Cui⁴, S. Zhu⁵, X. Zhang⁵, H. Shi⁶, S. Qie⁶, Y. Wang⁷, Y. Ma⁷, ¹Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, ²Cancer Hospital of Chongqing University, Chongqing, China, ³The First Hospital of Jilin University, Changchun, China, ⁴Liaoning Cancer Hospital & Institute, Shenyang, China, ⁵The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, ⁶Affiliated Hospital of Hebei University, Baoding, China, ⁷General Hospital of Ningxia Medical University, Yinchuan, China
- 20:30 - 20:30 **69P - Impact of pembrolizumab duration and comedications on overall survival: analysis from 45 000 patients with advanced NSCLC**
- Adrien Rousseau¹, S. Foulon², S. Michiels², A. Lolivier², D. Planchard¹, F. Barlesi¹, J. Remon Masip¹, P. Lavaud¹, M. Aldea¹, M. Frelaut¹, C. Le Pechoux¹, A. Botticella¹, A. Levy¹, A. Gazzah¹, B. Besse³, ¹Institut Gustave Roussy, Villejuif, Cedex, France, ²Gustave Roussy - Cancer Campus, Villejuif, France, ³Institut Gustave Roussy, Villejuif, France
- 20:30 - 20:30 **73P - Camrelizumab plus famitinib as first-line treatment in patient with locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE)?A multi-center, single-arm, phase II study**
- Qian Chu¹, J. Jiang², B. Yang³, S. Cang⁴, Q. Song⁵, J. Wang⁶, F. Ye⁷, H. Wang⁸, X. Liu⁹, ¹Tongji Hospital of Tongji Medical College, Wuhan, China, ²Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ³Hubei Cancer Hospital, Wuhan, China, ⁴Henan Provincial People's Hospital, Zhengzhou, China, ⁵Renmin Hospital of Wuhan University, Wuhan, China, ⁶The First Affiliated Hospital of Shandong First Medical University, Jinan, China, ⁷The First Affiliated Hospital of Xiamen

University, Xiamen, China, ⁸Henan Cancer Hospital, Zhengzhou, China, ⁹The Second Xiangya Hospital of Central South University, Changsha, China

- 20:30 - 20:30 **74P - A single-center, Phase II study of surufatinib combined with toripalimab, pemetrexed(A), and platinum (P) in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC)**
- Wen Feng Fang¹, Y. Yang², Y. Huang², Y. Zhao², Y. Zhang², T. Zhou², G. Chen², S. Zhao², Y. Ma², S. Hong², H. Zhao², L. Zhang², ¹Sun Yat-Sen University Cancer Center, Guangzhou, China, ²Sun Yat-sen University Cancer Center, Guangzhou, China
- 20:30 - 20:30 **71P - Real-world analysis of first-line maintenance (1LM) immunotherapy (IO) for nonsquamous (NSQ) advanced/metastatic non-small lung cancer (a/mNSCLC) without targetable mutations**
- Umit Tapan¹, M. Shah², K. Bell², A. Aziez³, X. Sun⁴, M. Du⁵, E. Du⁵, Q. Hua⁵, H. Yang⁵, ¹Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, United States of America, ²GSK, Collegeville, United States of America, ³GSK, Basel, Switzerland, ⁴Former employee of GSK, Research Triangle, United States of America, ⁵Analysis Group, Boston, United States of America
- 20:30 - 20:30 **75P - Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC): EMPOWER-lung 3 liver metastases subpopulation**
- Ana Baramidze¹, C. Gessner², M. Gogishvili³, A. Sezer⁴, T. Makharadze⁵, S. Kilickap⁶, M. Gumus⁷, X. He⁸, G. Gullo⁸, P. Rietschel⁸, R. Quek⁸, ¹Todua Clinic, Tbilisi, Georgia, ²POIS Leipzig GbR, Leipzig, Germany, ³University Clinic Ltd, Tbilisi, Georgia, ⁴Baskent University, Ankara, Turkey, ⁵LTD High Technology Hospital Med Center, Tbilisi, Georgia, ⁶Hacettepe University - Faculty of Medicine, Ankara, Turkey, ⁷Istanbul Medeniyet University, Istanbul, Turkey, ⁸Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America
- 20:30 - 20:30 **76P - Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O Optimise analysis**
- Gregoire Justeaux¹, M. Perol², C. Audigier Valette³, D. Debievre⁴, X. Quantin⁵, H. Lena⁶, P. Macouillard⁷, L. Bosquet⁷, M. Schoemaker⁸, M. Mella⁹, B. Correia¹⁰, C. Rault¹¹, M. Daumont¹², J. Penrod¹³, C. Chouaid¹⁴, ¹CHU Angers, Angers, Cedex 9, France, ²Centre Léon Bérard, Lyon, France, ³Hopital Sainte Musse, Toulon, France, ⁴GHRMSA, Mulhouse, France, ⁵ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, France, ⁶Hop Pontchaillou, Rennes, France, ⁷Unicancer, Paris, Cedex, France, ⁸IQVIA Nederland, Amsterdam, Netherlands, ⁹IQVIA Italy, Cassina De' Pecchi, Italy, ¹⁰IQVIA Portugal, Porto Salvo, Portugal, ¹¹Data Gnosis, Rennes, France, ¹²Bristol Myers Squibb Belgium SA, Brussels, Belgium, ¹³Bristol Myers Squibb, Princeton, United States of America, ¹⁴CH Intercommunal de Créteil, Créteil, France
- 20:30 - 20:30 **78P - Final Analysis of the French Real-World Study EVIDENS: Effectiveness, Safety & Quality of Life At 36 Months of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)**

Fabrice Barlesi¹, A. Dixmier², D. Debieuvre³, C. Raspaud⁴, J.B. Auliac⁵, N. Benoit⁶, P. Bombaron⁷, D. Moro-Sibilot⁸, B. Asselain⁹, C. Audigier-Valette¹⁰, F. Brellier¹¹, F.-E. Cotté¹², M. Perol¹³, ¹Institut Gustave Roussy, Villejuif, Cedex, France, ²C.H.R. Orléans - La source, Orléans, France, ³GHRMSA, Mulhouse, France, ⁴Clinique Saint Exupéry, Toulouse, France, ⁵C.H.I. - Centre Hospitalier Intercommunal de Créteil, Créteil, Cedex, France, ⁶Clinique de l'Europe, Amiens, France, ⁷Hôpital privé Jean Mermoz, Lyon, France, ⁸University Hospital of Grenoble, La Tronche, France, ⁹Institut Curie, Paris, France, ¹⁰C.H. Sainte Musse, Toulon, France, ¹¹Bristol Myers Squibb Pharmaceuticals Limited, Uxbridge, United Kingdom, ¹²Bristol-Myers Squibb, Rueil-Malmaison, France, ¹³Centre Léon Bérard, Lyon, France

- 20:30 - 20:30 **77P - A single-arm trial of BACE plus tislelizumab in patients with NSCLC: updated analysis**
Xuhua Duan, H. Li, D. Kuang, M. Zhang, W. Xu, C. Liang, J. Wang, J. Ren, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- 20:30 - 20:30 **79P - A prospective, single-arm, phase II study to evaluate the efficacy and safety of Tislelizumab plus chemotherapy in resectable NSCLC**
Daqiang Sun, M. Wang, Tianjin Chest Hospital, Tianjin, China
- 20:30 - 20:30 **80P - Efficacy and Safety of Tislelizumab Combined with Anlotinib and 2-cycles Chemotherapy as First-line Treatment for Advanced NSCLC(TISAL-FE-01)**
Jun Tang¹, X. Qian², J. Luo², S. Lin², J. Xu², Y. Zhou², Z. Li², Y. Zeng², B. Li², H. Lin², ¹The Second Affiliated Hospital of Hainan Medical College, Haikou City, China, ²The Second Affiliated Hospital of Hainan Medical University, Haikou, China
- 20:30 - 20:30 **81P - Real-World Experience with Docetaxel Regimens in Metastatic Non-Squamous (mNSq) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Platinum-Based Chemotherapy (PCT) and an Immune Checkpoint Inhibitor (ICI) in the United States (US)**
Marisa Bittoni¹, S. Keeping², D. Carbone³, J. Park², A.T. Nguyen⁴, K. Toor², N. Petruski-Ivleva⁵, A.K. Vadanahalli Shankar⁵, G. Konidaris⁶, ¹The Ohio State University - OSU Wexner Medical Center, Columbus, United States of America, ²Precision Medicine Group, LLC, Vancouver, Canada, ³The Ohio State University, BRT, Columbus, United States of America, ⁴Precision Medicine Group, LLC, Boston, United States of America, ⁵Sanofi, Cambridge, United States of America, ⁶Sanofi, Reading, United Kingdom
- 20:30 - 20:30 **82P - The Role of Circadian Rhythms in NSCLC Immunotherapy Efficacy: A Focus on First Dose Timing**
Martin Igor Gomez-Randulfe Rodriguez, M. Pearce, F. Gomes, C. Lindsay, Y. Summers, F. Blackhall, L. Cove-Smith, S. Hughes, P. Taylor, R. Califano, The Christie NHS Foundation Trust, Manchester, United Kingdom
- 20:30 - 20:30 **83P - Association of immune-related adverse events and the efficacy of anti-PD-(L)1 monotherapy in patients with advanced NSCLC: a cohort study adjusting for immortal-time bias**
Yun Fan, Y. Yu, Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, China

20:30 - 20:30

84P - Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase 3 CAPSTONE-1 study

Ying Cheng¹, J. Wang², C. Zhou³, W. Yao⁴, Q.-M. Wang⁵, X. Min⁶, G. Chen⁷, X. Xu⁸, X.-Y. Li⁹, F. Xu¹⁰, Y. Fang¹¹, R. Yang¹², G. Yu¹³, Y. Gong¹⁴, J. Zhao¹⁵, Y. Fan¹⁶, Q. Liu¹⁷, L. Cao¹⁸, X. Li¹⁹, K. Ma¹⁹, ¹Jilin Cancer Hospital, Changchun, China, ²National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, ⁴Sichuan Cancer Hospital & Institute, Chengdu, China, ⁵Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, ⁶Anhui Chest Hospital, Hefei, China, ⁷Harbin Medical University Cancer Hospital, Harbin, China, ⁸Northern Jiangsu People's Hospital, Yangzhou, China, ⁹The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ¹⁰The First Affiliated Hospital of Nanchang University, Guangzhou, China, ¹¹Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, ¹²Yunnan Cancer Hospital, Kunming, China, ¹³Weifang People's Hospital, Weifang, China, ¹⁴West China Hospital, Sichuan University, Chengdu, China, ¹⁵Beijing Cancer Hospital, Beijing, China, ¹⁶Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, China, ¹⁷Affiliated Hospital of Jiangnan University, Wuxi, China, ¹⁸Anhui Provincial Hospital/Affiliated Hospital of University of Science and Technology of China, Hefei, China, ¹⁹Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China

20:30 - 20:30 **85P - Phase II trial of tislelizumab plus sitravatinib as maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC)**

Yun Fan¹, H. Li¹, K. Chen¹, L. Gong¹, Z. Huang¹, Y. Xu¹, X. Yu², G. Lou¹, H. Lu¹, W. Hong¹, J. Zhao¹, W. Wang¹, C. Gu¹, F. Xie¹, X. Xu¹, N. Han¹, ¹Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, China, ²Zhejiang Cancer Hospital, Hangzhou, China

20:30 - 20:30 **86P - Durvalumab plus Olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): updated efficacy and safety analysis**

Yan Huang¹, J. Jia², Q.-M. Wang³, L. Zhang¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, China, ²Dongguan People's Hospital, dongguan, China, ³Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

20:30 - 20:30 **88P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)**

Mara Persano¹, T. Tada², G. Suda³, S. Shimose⁴, M. Kudo⁵, C. Yoo⁶, J. Cheon⁷, F. Finkelmeier⁸, H.Y. Lim⁹, J. Presa¹⁰, G. Masi¹¹, F. Bergamo¹², M. Iavarone¹³, G. Cabibbo¹⁴, F.G. Foschi¹⁵, F. Piscaglia¹⁶, S. Cascinu¹⁷, M. Scartozzi¹⁸, A. Casadei Gardini¹⁷, ¹AOU di Cagliari - Ospedale Civile, Cagliari, Italy, ²Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ³Hokkaido University Hospital, Sapporo, Japan, ⁴Kurume University Hospital, Kurume, Japan, ⁵Kindai University - Faculty of Medicine, Osaka, Japan, ⁶Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of, ⁷Ulsan University Hospital, Ulsan, Korea, Republic of, ⁸Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, Germany, ⁹Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul,

Korea, Republic of, ¹⁰rás-os-Montes e Alto Douro Hospital Centre, Vila real, Portugal, ¹¹AOU Pisana - Stabilimento di Santa Chiara, Pisa, Italy, ¹²Veneto Institute of Oncology IOV - IRCCS, Padua, Italy, ¹³Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, Italy, ¹⁴University of Palermo, Palermo, Italy, ¹⁵Ospedale di Faenza, Faenza, Italy, ¹⁶AOU Policlinico S. Orsola-Malpighi, Bologna, Italy, ¹⁷IRCCS Ospedale San Raffaele, Milan, Italy, ¹⁸University of Cagliari, Cagliari, Italy

- 20:30 - 20:30 **89P - Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: a single arm phase 2 trial**
Liang Ma¹, Z. Deng², L.-N. Qi², Z.-S. Chen², Z.-M. Zhang², B.-D. Xiang², J.-H. Zhong², ¹Guangxi Medical University Affiliated Tumor Hospital, Nanning, China, ²Guangxi Medical University Cancer Hospital, Nanning, China
- 20:30 - 20:30 **90P - HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): a phase II trial**
Haibin Zhang, W. Lu, Y. Fu, X. Li, W. Dong, N. Zhu, J. Zhai, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China
- 20:30 - 20:30 **91P - A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma**
Wei Zhang, W. Ding, C. Hu, Y. Yang, J. Mao, J. Gong, P. Tang, Y. Wu, Y. Zhang, Z. Chen, Affiliated Hospital of Nantong University, Nantong, China
- 20:30 - 20:30 **92P - TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A propensity score matching study**
Hongjie Cai, S. Tang, W. Guo, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
- 20:30 - 20:30 **93P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: a real-world, retrospective, multicentric study.**
Margherita Rimini¹, M. Persano², L. Fornaro³, L. Antonuzzo⁴, S. Lonardi⁵, L. Rimassa⁶, M. Niger⁷, M. Silletta⁸, E. Tamburini⁹, G. Giordano¹⁰, M. Scartozzi¹¹, A. Pastorino¹², E. Martinelli¹³, M.D. Rizzato⁵, A. Casadei Gardini¹, ¹IRCCS Ospedale San Raffaele, Milan, Italy, ²AOU di Cagliari - Ospedale Civile, Cagliari, Italy, ³AOU Pisana - Stabilimento di Santa Chiara, Pisa, Italy, ⁴AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy, ⁵IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy, ⁶IRCCS Humanitas Research Hospital, Rozzano, Italy, ⁷Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy, ⁸Policlinico Universitario Campus Bio-Medico, Rome, Italy, ⁹Azienda Ospedaliera Cardinale Giovanni Panico, Tricase, Italy, ¹⁰Ospedale "Sacro Cuore di Gesù" Fatebenefratelli, Benevento, Italy, ¹¹University of Cagliari, Cagliari, Italy, ¹²IRCCS Ospedale Policlinico San Martino, Genova, Italy, ¹³Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
- 20:30 - 20:30 **94P - First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma**
Qin-Qin Liu¹, J. Yan², C.-N. Yang¹, Z.-J. Chen¹, H.-M. Lin¹, R. Zhang¹, ¹Sun Yat-Sen

University, Guangzhou, China, ²Sun Yat-Sen Memorial Hospital, Guangzhou, China

- 20:30 - 20:30 **95P - A single-arm, multicenter phase 2 trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)**
Junsheng Wang¹, N. Li², Y. Guo³, Y. Cheng⁴, B. Li⁵, S. Luo², ¹Anyang Cancer Hospital, Anyang, China, ²Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, ³The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ⁴Qilu Hospital of Shandong University, Jinan, China, ⁵Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
- 20:30 - 20:30 **96P - Cadonilimab combined with taxane and cisplatin as the first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): an open-label, multicenter phase 2 trial (AK104-IIT-014)**
Wang Qu¹, G. Jing², Y. Liu², B. Zhang², Y. Guo², M. Yang³, J. Huang², ¹Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²National Cancer Center/National Clinical Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Shanxi Cancer Hospital, Taiyuan, China
- 20:30 - 20:30 **97P - ICI for patients with MSS metastatic colorectal cancer**
Zayana Sangadzhieva¹, G. Mamedova², ¹FGAOU VO First MGMU im. THEM. Sechenov Moscow State Medical University (Sechenov University), Moscow, Russian Federation, ²Volgograd State Medical University, Volgograd, Russian Federation
- 20:30 - 20:30 **99P - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer**
Hongnan Mo, J. Zhai, J. Han, H. Ge, Y. Wei, X. Guan, H. Qian, F. Ma, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China
- 20:30 - 20:30 **98P - Short-course Radiotherapy based Total Neoadjuvant Therapy combined with Tislelizumab in the Treatment of Locally Advanced Rectal Cancer: Mid-term Report of a Phase II, Open-Label, Randomized Controlled Trial**
Wu Fengpeng¹, L. Xiao², C. Zhou³, W. Niu¹, C. Yang², X. Hu³, H. Ma³, G. Wang³, J. Zhang³, B. Yu³, G. An³, Y. Gao², M. Liu², F. Qu², B. Zhao², D. Liu², C. Gao², J. Wang², G. Wang³, ¹The Fourth Hospital of Hebei Medical University/ Hebei Cancer Hospital - East Campus, Shijiazhuang, China, ²The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, ³The Fourth Hospital of Hebei Medical University - North Gate, Shijiazhuang, China
- 20:30 - 20:30 **100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results**
Jianqing Zhu¹, H. Yu², M. Pan³, H. Chao⁴, Y. Gao⁵, S. Niu⁶, H. Zhao⁷, Y. Chen⁸, Q. Wen⁹, ¹Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, China, ²Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, ³Maternal and Child Health Hospital of Jiangxi Province, Nanchang, China, ⁴The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China, ⁵Liaoning Cancer Hospital & Institute, Shenyang, China,

⁶The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, ⁷The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁸The First Affiliated Hospital Of Soochow University, Suzhou, China, ⁹Zhejiang Cancer Hospital, Hangzhou, China

- 20:30 - 20:30 **101P - Progression-Free Survival is an acceptable surrogate endpoint for chemo-immunotherapy combinations in Cervical Carcinoma, an EORTC Young GCG study**
- Ramon Yarza¹, M. Kountouri², H. Costa Guedes³, C. O'Gorman⁴, J.M. Estrada-Lorenzo⁵, C. Coens⁶, F. Herrera⁷, A. Madariaga⁵, ¹The Royal Marsden Hospital (Sutton), Sutton, United Kingdom, ²HUG - Hopitaux Universitaires de Genève, Geneva, Switzerland, ³CHVNG/E - Centro Hospitalar de Vila Nova de Gaia/Espinho - Unidade 1 - EPE-SNS, Vila Nova de Gaia, Portugal, ⁴Trinity St. James Cancer Institute, Dublin, Ireland, ⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, Belgium, ⁷CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- 20:30 - 20:30 **102P - Interim safety analysis of a phase 2 trial of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer**
- Oladapo Yeku¹, A. Russo², A. Bregar³, J. Brower⁴, A. Dinesh⁴, S. Bouberhan², P. Widick⁵, J. Jang⁵, T. Colella², J. Filipi², E. Eisenhauer², C. Kournioti⁶, A. Goodman², D. Spriggs², H. Lee², C. Castro², ¹Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States of America, ²MGH - Massachusetts General Hospital, Boston, United States of America, ³Massachusetts General Hospital - Allergy Associates, Boston, United States of America, ⁴Wentworth-Douglass Hospital, Dover, United States of America, ⁵Beth Israel Deaconess Medical Center, Boston, United States of America, ⁶Newton-Wellesley Hospital, Washington St, Newton, MA, United States of America
- 20:30 - 20:30 **103P - Long-term survivorship rates among previously treated patients with advanced renal cell carcinoma (aRCC) achieving objective response with nivolumab**
- Saby George¹, J. Larkin², K. Chepynoga³, L.M. Garcia Fernandez⁴, J. May⁵, M. Dyer⁵, M. Patel⁶, M. Kurt⁶, ¹Roswell Park Comprehensive Cancer Center, Buffalo, United States of America, ²The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom, ³Parexel, Hørsholm, Denmark, ⁴Novo Nordisk Pharma S.A, Madrid, Spain, ⁵Bristol Myers Squibb, Uxbridge, United Kingdom, ⁶Bristol Myers Squibb, Princeton, United States of America
- 20:30 - 20:30 **104P - Bladder-Sparing Treatment for muscle-invasive bladder carcinoma (MIBC): A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy.**
- Yu Zeng, Liaoning Cancer Hospital & Institute, Shenyang, China
- 20:30 - 20:30 **105P - Preliminary efficacy and safety results from 'ReBirth', a phase II study of risk-based bladder-sparing therapy for MIBC.**
- Yijun Shen¹, X. Lu², X. Ma², W. Liu², D. Ye², ¹Fudan University Shanghai cancer center, Shanghai, China, ²Fudan University Shanghai Cancer Center, Shanghai, China

- 20:30 - 20:30 **106P - Treatment Sequencing in PD-L1-Positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Exploratory Analysis of the Phase 3 KEYNOTE-048 Study**
- R. Greil¹, B. Burtneess², S. Laban³, I. Brana⁴, R. Mesia Nin⁵, T. Fueereder⁶, Å. Bratland⁷, L. Licitra⁸, T. Rordorf⁹, Amanda Psyrrri¹⁰, A. Popovtzer¹¹, B. Hughes¹², M. Tahara¹³, J. Lin¹⁴, B. Gumuscu¹⁴, N. Lerman¹⁴, K. Harrington¹⁵, ¹Paracelsus Medizinische Privatuniversität, Salzburg, Austria, ²Yale University School of Medicine - Yale Cancer Center, New Haven, United States of America, ³University of Ulm, Ulm, Germany, ⁴Hospital Vall d'Hebron, Barcelona, Spain, ⁵Catalan Institut of Oncology, Barcelona, Spain, ⁶Medical University of Vienna, Vienna, Austria, ⁷Oslo University Hospital, Oslo, Norway, ⁸Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy, ⁹University Hospital Zürich, Zurich, Switzerland, ¹⁰Attikon University Hospital, Athens, Greece, ¹¹Sharett Institute of Oncology at the Hadassah University Hospital, Jerusalem, Israel, ¹²Royal Brisbane and Women's Hospital and University of Queensland, Herston, Australia, ¹³National Cancer Center Hospital East, Kashiwa, Japan, ¹⁴Merck & Co., Inc., Rahway, United States of America, ¹⁵ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, United Kingdom
- 20:30 - 20:30 **108P - Real-world (RW) effectiveness and safety of adjuvant nivolumab (NIVO) in patients (pts) with melanoma in Belgium and Luxembourg: PRESERV MEL**
- Bart Neyns¹, L. Willemot², L. Mcdonald³, H. Van Campenhout², G. Berchem⁴, C. Jacobs⁵, A. Rogiers⁶, N. Blockx⁷, A. Rorive⁸, ¹Vrije Universiteit Brussel - Faculty of Medicine & Pharmacy, Brussels, Belgium, ²Bristol Myers Squibb, Braine L'Alleud, Belgium, ³Bristol Myers Squibb, Uxbridge, United Kingdom, ⁴Centre Hospitalier de Luxembourg and University of Luxembourg, Luxembourg, Luxembourg, ⁵Universitair Ziekenhuis Gent, Gent, Belgium, ⁶Centre Hospitalier Universitaire Brugmann, Jette, Belgium, ⁷Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium, ⁸Centre Hospitalier Universitaire de Liège Sart-Tilman, Liège, Belgium
- 20:30 - 20:30 **109P - Prognosis of patients with metastatic melanoma with initial stable disease during treatment with anti-PD-1 monotherapy**
- Inge Noringriis¹, M. Donia¹, L. Bastholt², H. Schmidt³, C. Haslund⁴, E. Ellebæk⁵, I.M. Svane¹, ¹Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark, ²OUH - Odense University Hospital, Odense, Denmark, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Aalborg University Hospital, Aalborg, Denmark, ⁵Department of Oncology, Herlev Hospital, Copenhagen University, Herlev, Denmark
- 20:30 - 20:30 **110P - Outcomes of CUPem: A prospective Phase II multicentre clinical Trial of Pembrolizumab in patients with pre-treated Cancer of Unknown Primary**
- Harpreet Wasan¹, S. Rao², S. Ngan³, C. Matei⁴, A. Sita-Lumsden⁵, L. Webber⁴, J. Mencil⁶, R. Elliott¹, J. Lozano-Kuehne⁴, ¹Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, United Kingdom, ²The Royal Marsden Hospital - Chelsea, London, United Kingdom, ³Guy's and St. Thomas' Hospital NHS Trust, London, United Kingdom, ⁴Imperial College London - South Kensington Campus, London, United Kingdom, ⁵Guy's Cancer Centre, London, United Kingdom, ⁶The Royal Marsden Hospital (Sutton), Sutton, United Kingdom
- 20:30 - 20:30 **111P - Characteristics and outcomes of immunotherapy-related liver injury in**

patients with hepatocellular carcinoma compared to patients with advanced solid tumours

Ciro Celsa¹, G. Cabibbo², T. Marron³, A. Saeed⁴, M. Pinter⁵, Y.-H. Huang⁶, A. Pillai⁷, M. Schoenlein⁸, J. Von Felden⁸, P. Galle⁹, M. Kudo¹⁰, L. Rimassa¹¹, A. Singal¹², H. Chon¹³, W.-F. Hsu¹⁴, L. Brunetti¹⁵, C. Pinto¹⁶, M. Bersanelli¹⁷, A. Cortellini¹⁸, D. Pinato¹⁹,
¹Imperial College London - Hammersmith Campus, London, United Kingdom, ²University of Palermo, Palermo, Italy, ³Icahn School of Medicine at Mount Sinai, New York, United States of America, ⁴KUMC - University of Kansas Medical Center, Kansas City, United States of America, ⁵Medical University of Vienna, Vienna, Austria, ⁶Taipei Veterans General Hospital, Taipei City, Taiwan, ⁷The University of Chicago, Chicago, United States of America, ⁸University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁹Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany, ¹⁰Kindai University - Faculty of Medicine, Osaka, Japan, ¹¹IRCCS Humanitas Research Hospital, Rozzano, Italy, ¹²UTSW - University of Texas Southwestern Medical Center, Dallas, United States of America, ¹³CHA Bundang Medical Center, Seongnam, Korea, Republic of, ¹⁴China Medical University, Taichung City, Taiwan, ¹⁵Policlinico Universitario Campus Bio-Medico, Rome, Italy, ¹⁶Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, ¹⁷University Hospital of Parma, Parma, Italy, ¹⁸Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ¹⁹Imperial College London - Hammersmith Hospital, London, United Kingdom

20:30 - 20:30 **112P - Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors**

Danielle Delombaerde¹, N. Van De Veire², D. Vervloet², V. Moerman², L. Van Calster², L. Croes¹, F. Gremontprez², A. De Meulenaere², X. Elzo Kraemer², K. Wouters³, M. Peeters⁴, H. Prenen⁴, J. De Sutter², ¹AZ Maria Middelaes AZMMSJ and Center for Oncological Research (CORE), University of Antwerp, Gent, Belgium, ²AZ Maria Middelaes AZMMSJ, Gent, Belgium, ³Antwerp University Hospital - Center for Oncological Research (CORE), Edegem, Belgium, ⁴UZA - University Hospital Antwerp, Edegem, Belgium

20:30 - 20:30 **113P - A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management**

Monica Valente¹, V. Vegni², V. Croce³, C. Bellan⁴, G. Rossi⁵, G. Gibilisco³, F. Frongia³, R. Guazzo⁴, C. Ghiribelli⁴, V. Savelli⁴, M. Ravara³, T. Sani³, E. Simonetti³, M. Maio¹, L. Calabro⁶, A. Di Giacomo¹, ¹AOU Senese - Santa Maria delle Scotte, Siena, Italy, ²NIBIT Foundation Onlus, Siena, Italy, ³University of Siena and Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy, ⁴University of Siena, Siena, Italy, ⁵Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy, ⁶University of Ferrara, Ferrara, Italy

20:30 - 20:30 **114P - Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study**

Annelies Verbiest¹, D. Delombaerde², M. Verhaert³, L. Tack⁴, C. Oeste⁵, L. Cool⁴, L. Croes², I. Bassez⁵, D. Hens⁵, C. Franssen⁶, S. Aspeslagh³, V. Geldhof⁷, P. Debruyne⁴, C. Vulsteke², ¹UZA - University Hospital Antwerp, Edegem, Belgium, ²AZ Maria Middelaes AZMMSJ and Center for Oncological Research (CORE), University of Antwerp, Gent, Belgium, ³Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium, ⁴General Hospital AZ Groeninge, Kortrijk, Belgium, ⁵LynxCare Clinical Informatics N.V., Leuven, Belgium, ⁶Antwerp University Hospital and

CardioVascular Research Group, GENCOR Research Unit, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium, ⁷General Hospital AZ Klina and General Hospital AZ Voorkempen, Antwerp, Belgium

20:30 - 20:30 **115TiP - MDT-BRIDGE: A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC**

Martin Reck¹, E. Nadal², N. Girard³, A.R. Filippi⁴, L. Martin⁵, C. Gay⁶, C. Petersen⁷, D. Gale⁸, H. Bridge⁹, N. Donner⁸, N. Georgoulia¹⁰, J. Spicer¹¹, ¹Krankenhaus Grosshansdorf, Grosshansdorf, Germany, ²Institut Català d'Oncologia - ICO Hospitalet, Barcelona, Spain, ³Institut du Thorax Curie Montsouris, Institut Curie and UVSQ, Paris Saclay, Paris/Versailles, France, ⁴Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy, ⁵University of Virginia, Charlottesville, United States of America, ⁶University of Texas MD Anderson Cancer Center, Houston, United States of America, ⁷University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁸AstraZeneca, Cambridge, United Kingdom, ⁹AstraZeneca, Macclesfield, United Kingdom, ¹⁰AstraZeneca, Gaithersburg, United States of America, ¹¹McGill University, Montreal, Canada

20:30 - 00:45 **117TiP - BGB-HNSCC-201 (NCT05909904): Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts) With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)**

Kevin Harrington¹, Y. Guo², R. Haddad³, H.R. Kim⁴, C. Perez⁵, I. Xiang⁶, H. Li⁷, G. Dong⁸, C.J. Yen⁹, C. Even¹⁰, L. Locati¹¹, S. Qiu¹², ¹ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, United Kingdom, ²Shanghai East Hospital, Shanghai, China, ³Dana-Farber Cancer Institute, Boston, United States of America, ⁴Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ⁵Florida Cancer Specialists and Sarah Cannon Research Institute, Orlando, United States of America, ⁶BeiGene USA, Inc., San Mateo, United States of America, ⁷BeiGene (Shanghai) Co., Ltd., Shanghai, China, ⁸BeiGene USA, Inc., Ridgefield Park, United States of America, ⁹National Cheng Kung University Hospital, Tainan, Taiwan, ¹⁰Institut Gustave Roussy, Villejuif, France, ¹¹Translational and clinical research for medical oncology, University of Pavia, Pavia, Italy, ¹²Fujian Cancer Hospital, Fujian, China

00:45 - 00:45 **121P - MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) With/Without Docetaxel in Metastatic NSCLC After Platinum-Chemotherapy (Chemo) and Immunotherapy**

Nir Peled¹, J. Mazieres², D. Kowalski³, W.-S. Lam⁴, M. Hochmair⁵, M. Majem⁶, S.H. Kim⁷, A. Calles Blanco⁸, K. Cuppens⁹, I. Casarini¹⁰, O. Bylicki¹¹, B. Shim¹², J. Sørensen¹³, M. Gilli¹⁴, S.H. How¹⁵, C. Schumann¹⁶, C. Gonzalez Arenas¹⁷, T. He¹⁸, A. Samkari¹⁸, S. Novello¹⁹, ¹Shaare Zedek Medical Center, Jerusalem, Israel, ²Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ³Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland, ⁴Fiona Stanley Hospital, Perth, Australia, ⁵Klinik Floridsdorf, Vienna, Austria, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁷Seoul National University Bundang Hospital, Seongnam, Korea, Democratic People's Republic of, ⁸Hospital General Universitario Gregorio Marañón,

Madrid, Spain, ⁹UHasselt, Faculty of Medicine and Life Sciences - LCRC, Hasselt University, Diepenbeek, Belgium, ¹⁰Hospital Bernardo Houssay, Mar del Plata, Argentina, ¹¹Hôpital d'Instruction des Armées Sainte Anne, Toulon, France, ¹²The Catholic University of Korea, St. Vincent's Hospital, Suwon, Korea, Republic of, ¹³Rigshospitalet, Copenhagen, Denmark, ¹⁴Azienda Ospedaliera dei Colli - Monaldi, Naples, Italy, ¹⁵Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Pahang, Malaysia, ¹⁶Klinikverbund Allgäu, Kempten, Germany, ¹⁷MSD, Madrid, Spain, ¹⁸Merck & Co., Inc., Rahway, United States of America, ¹⁹Università Degli Studi Di Torino - AOU San Luigi, Orbassano, Italy

00:45 - 00:45

122P - Casdozokitug (casdozo, SRF388), a first-in-class IL-27 targeting antibody, as monotherapy (monotx) or in combination with pembrolizumab (pembro) in treatment-refractory non-small cell lung cancer (NSCLC)

Thomas Marron¹, A. Naing², C. Mantia³, N. Pennell⁴, H.R. Kim⁵, L. Villaruz⁶, A. El-Khoueiry⁷, D. Gerber⁸, A. Qin⁹, T.-Y. Kim¹⁰, M. Altan², L. Gandhi³, L. Appleman¹¹, S. Yoon¹², J. Hill¹³, V. Reichert¹³, R. Masia¹³, L. Harshman¹³, A. Patnaik¹⁴, D. Morgensztern¹⁵, ¹Icahn School of Medicine at Mount Sinai, New York, United States of America, ²The University of Texas M. D. Anderson Cancer Center, Houston, United States of America, ³Dana Farber Cancer Institute, Boston, United States of America, ⁴Taussig Cancer Center-Cleveland Clinic, Cleveland, United States of America, ⁵Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ⁶University of Pittsburgh Medical Center, Pittsburgh, United States of America, ⁷Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, United States of America, ⁸Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, United States of America, ⁹University of Michigan, Ann Arbor, United States of America, ¹⁰Seoul National University Hospital, Seoul, Korea, Republic of, ¹¹University of Pittsburgh Cancer Institute, Pittsburgh, United States of America, ¹²Asan Medical Center - University of Ulsan, Seoul, Korea, Republic of, ¹³Surface Oncology, Inc., Cambridge, United States of America, ¹⁴South Texas Accelerated Research Therapeutics (START), San Antonio, United States of America, ¹⁵Washington University School of Medicine in St. Louis, St. Louis, United States of America

00:45 - 00:45

107P - Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locally advanced squamous cell carcinoma of the head and neck

Kunyu Yang¹, X. Zhang², B. Wu², X. Liu², Z. Zhang², G. Peng², G. Xiao², J. Huang², Q. Ding², ¹Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ²Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Cancer Center Union Hospital, Wuhan, China

00:45 - 00:45

123P - A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: the run-in phase of the NIBIT Foundation ML1 Study

Anna Di Giacomo¹, G. Rossi², L. Calabro³, A. Pascucci², V. Vegni⁴, E. Simonetti⁵, M. Colucci⁵, M. Valente², G. Gibilisco⁵, F. Frongia⁵, M.F. Lofiego⁶, G. Amato², H. Keer⁷, A. Oganesian⁷, D. Chan⁷, D. Giannarelli⁸, M. Ceccarelli⁹, A. Anichini¹⁰, A. Covre⁶, M. Maio¹, ¹AOU Senese - Santa Maria delle Scotte, Siena, Italy, ²Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy, ³University of Ferrara, Ferrara, Italy, ⁴NIBIT Foundation Onlus, Siena, Italy, ⁵University of Siena and Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy, ⁶University of Siena, Siena, Italy, ⁷Astex

Pharmaceuticals, Inc., Pleasanton, United States of America, ⁸Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, ⁹Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, United States of America, ¹⁰Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

00:45 - 00:45

124P - Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC) -Updated results of a phase 2b trial

Wen Feng Fang¹, Y. Yang², Y. Huang², Y. Zhao², Y. Zhang², T. Zhou², G. Chen², S. Zhao², Y. Ma², S. Hong², H. Zhao², L. Zhang², ¹Sun Yat-Sen University Cancer Center, Guangzhou, China, ²Sun Yat-sen University Cancer Center, Guangzhou, China

00:45 - 00:45

126P - Evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer

Oladapo Yeku¹, M. Barve², W. Tan³, J. Wang⁴, A. Patnaik⁵, P. Lorusso⁶, A.-R. Naqash⁷, A. Dowlati⁸, S. Fu⁹, M. Gordon¹⁰, J. Hubbard¹¹, S. Kummer¹², C. Kyriakopoulos¹³, E. Schenk¹⁴, D. Deegan¹⁵, L. Liang¹⁵, Y. Li¹⁵, L. Reyno¹⁵, M. Chamberlain¹⁵, I. Winer¹⁶, ¹Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States of America, ²Mary Crowley Cancer Research Center, Dallas, United States of America, ³Mayo Clinic - Florida, Jacksonville, United States of America, ⁴Florida Cancer Specialists, Fort Myers, United States of America, ⁵South Texas Accelerated Research Therapeutics (START), San Antonio, United States of America, ⁶Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, United States of America, ⁷Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City, United States of America, ⁸University Hospitals Cleveland Medical Center, Cleveland, United States of America, ⁹The University of Texas M. D. Anderson Cancer Center, Houston, United States of America, ¹⁰HonorHealth Research Institute, Scottsdale, United States of America, ¹¹Allina Health Cancer Institute, Minneapolis, United States of America, ¹²OHSU Knight Cancer Institute - Center for Health and Healing Building 1 - South Waterfront, Portland, United States of America, ¹³UW Carbone Cancer Center, Madison, United States of America, ¹⁴University of Colorado Denver - Anschutz Medical Campus, Aurora, United States of America, ¹⁵Pionyr Immunotherapeutics, Inc., South San Francisco, United States of America, ¹⁶Wayne State University School of Medicine; Barbara Ann Karmanos Cancer Institute, Detroit, United States of America

00:45 - 05:00

116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer

Eric Van Cutsem¹, M. Fakih², N. Segal³, B. Johnson⁴, A. Kardosh⁵, A. Philipovskiy⁶, S. Krishnamurthi⁷, P. Gold⁸, J. Dekervel⁹, B. Schlechter¹⁰, J. Grossman¹¹, M.E. Elez Fernandez¹², N. Vardiashvili¹³, A. Azambuja¹⁴, C. Eng¹⁵, M. Ducreux¹⁶, T. André¹⁷, J. Tabernero¹², H.J. Lenz¹⁸, M. Hidalgo¹⁹, ¹University Hospitals Gasthuisberg, Leuven & University of Leuven, Leuven, Belgium, ²City of Hope Comprehensive Cancer Center, Duarte, United States of America, ³Memorial Sloan Kettering Cancer Center, New York, United States of America, ⁴The University of Texas MD Anderson Cancer Center, Houston, United States of America, ⁵OHSU - Oregon Health Science University, Portland, United States of America, ⁶Florida Cancer Specialists & Research Institute - Lake Mary Cancer Center, Lake Mary, United States of America, ⁷Taussig Cancer Center-Cleveland Clinic, Cleveland, United States of America, ⁸Swedish Cancer Institute - Medical

Oncology - First Hill, Seattle, United States of America, ⁹University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium, ¹⁰Dana Farber Cancer Institute, Boston, United States of America, ¹¹Agenus Inc - Corporate HQ, R&D and Vaccine Manufacturing, Lexington, United States of America, ¹²Vall d'Hebron University Hospital, Barcelona, Spain, ¹³Medical Center Innova, Tbilisi, Georgia, ¹⁴Hospital Mae de Deus, Porto Alegre, Brazil, ¹⁵Vanderbilt Ingram Cancer Center, Nashville, United States of America, ¹⁶Gustave Roussy - Cancer Campus, Villejuif, France, ¹⁷Hopital Saint-Antoine, Paris, France, ¹⁸University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, United States of America, ¹⁹NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, United States of America

05:00 - 05:00 **127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study**

Ira Winer¹, R. O'Cearbhaill², S. Boubherhan³, J. Hays⁴, R. Wenham⁵, D. Roque⁶, O. Yeku⁷, J. Liu⁸, B. Wang⁹, S.-Y. Yoo⁹, S. Govindraj⁹, M. Zhu⁹, J. Brouwer-Visser⁹, M. Peterman⁹, B. Barnes⁹, I. Lowy⁹, D. Knorr⁹, T. Uldrick⁹, E. Miller⁹, ¹"Wayne State University School of Medicine; Barbara Ann Karmanos Cancer Institute", Detroit, United States of America, ²Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, United States of America, ³MGH - Massachusetts General Hospital, Boston, United States of America, ⁴Ohio State University, Columbus, United States of America, ⁵Moffitt Cancer Center, Tampa, United States of America, ⁶Northwestern University, Evanston, United States of America, ⁷Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States of America, ⁸Dana Farber Cancer Institute, Boston, United States of America, ⁹Regeneron Pharmaceuticals, Inc., Tarrytown, United States of America

05:00 - 05:00 **128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab**

Gerald Falchook¹, K. Papadopoulos², A. Parikh³, A. Mahipal⁴, W. Messersmith⁵, G. Manji⁶, S. Fu⁷, E. Sherman⁸, D. Fein⁹, J. Krop¹⁰, C. Korth¹⁰, J. Wang¹¹, M. Sharma¹², D. Spigel¹³, A. Filipovic¹⁰, Z. Wainberg¹⁴, ¹Sarah Cannon Research Institute (SCRI) at HealthONE, Denver, United States of America, ²South Texas Accelerated Research Therapeutics (START), San Antonio, United States of America, ³MGH - Massachusetts General Hospital, Boston, United States of America, ⁴Mayo Clinic - Rochester, Rochester, United States of America, ⁵University of Colorado Denver, Denver, United States of America, ⁶New York-Presbyterian/Columbia University Irving Medical Center, New York, United States of America, ⁷The University of Texas M. D. Anderson Cancer Center, Houston, United States of America, ⁸MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America, ⁹Beth Israel Deaconess Medical Center, Boston, United States of America, ¹⁰PureTech Health LLC, Boston, United States of America, ¹¹Florida Cancer Specialists, Fort Myers, United States of America, ¹²START Midwest, Grand Rapids, United States of America, ¹³Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America, ¹⁴UCLA - David Geffen School of Medicine, Los Angeles, United States of America

05:00 - 05:00 **129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score**

Brian Kushner¹, J. Mora², G. Chan³, D. Morgenstern⁴, L. Amoroso⁵, K. Nysom⁶, J. Faber⁷, A. Wingerter⁸, M. Bear⁹, A. Rubio San Simón¹⁰, M. Düring¹¹, K. Tornøe¹¹, ¹Memorial

Sloan Kettering Cancer Center, New York, United States of America, ²Hospital Sant Joan de Déu Barcelona, Esplugues de Llobregat, Spain, ³HKU - The University of Hong Kong, Hong Kong, Hong Kong PRC, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁶Rigshospitalet, Copenhagen, Denmark, ⁷JGU Universitätsmedizin, Mainz, Germany, ⁸Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany, ⁹Indiana University - Bloomington, Bloomington, United States of America, ¹⁰Hospital Universitario Infantil Niño Jesús, Madrid, Spain, ¹¹Y-mAbs Therapeutics A/S, Hoersholm, Denmark

05:00 - 05:00

131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_δ)

Anna Di Giacomo¹, M. Simonelli², F. Santangelo¹, G. Amato³, E. Simonetti⁴, J. Graham⁵, M. Lahn⁶, G. Di Conza⁶, T. Hammett⁶, R. Zorrilla⁶, P. Kaur⁶, T. Ziyang⁷, T. Lakshmikanth⁷, P. Brodin⁷, M. Occhipinti⁸, C. Carlo-Stella⁹, A. Santoro¹⁰, P. Spiliopoulou⁵, T.R.J. Evans¹¹, M. Maio¹, ¹AOU Senese - Santa Maria delle Scotte, Siena, Italy, ²Humanitas University, Pieve Emanuele, Italy, ³Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy, ⁴University of Siena and Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy, ⁵BWSSC - Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, ⁶iOnctura SA, Geneva, Switzerland, ⁷Karolinska Institute, Stockholm, Sweden, ⁸Radiomics SA, Liège, Belgium, ⁹Humanitas University, Milan, Italy, ¹⁰Istituto Clinico Humanitas, Rozzano, Italy, ¹¹University of Glasgow, Glasgow, United Kingdom

05:00 - 05:00

132P - A phase I clinical trial of QLS31905 in advanced solid tumors

Yakun Wang¹, J. Gong², Y. Sun³, S. Yang⁴, M. Zhang⁵, J. Cui⁶, J. Lv⁷, H. Su⁸, J. Wang⁹, J. Lu¹⁰, J. Shan¹¹, J. Zhang¹², Y. Zhang¹³, Y. Li¹⁴, L. Gu¹⁴, L. Li¹⁴, X. Kang¹⁴, L. Shen², ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, China, ²Peking University Cancer Hospital and Institute, Beijing, China, ³Shandong Cancer Hospital and Institute, Jinan, China, ⁴Henan Cancer Hospital, Zhengzhou, China, ⁵The second Affiliated Hospital of Anhui Medical University, Hefei, China, ⁶The First Bethune Hospital of Jilin University, Changchun, China, ⁷The Affiliated Hospital of Qingdao University, Qingdao, China, ⁸Tangdu Hospital, Air Force Medical University, Xi'an, China, ⁹The Affiliated Hospital of Jining Medical College, Jining, China, ¹⁰Sichuan Cancer Hospital and Institute, Chengdu, China, ¹¹Army Medical Center of PLA, Chongqing, China, ¹²Liaoning Cancer Hospital, Shenyang, China, ¹³Cancer Hospital Affiliated to Harbin Medical University, Harbin, China, ¹⁴Qilu Pharmaceutical Co., Ltd., Jinan, China

05:00 - 05:00

133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors

Diwakar Davar¹, J. Knecht², A. Vandross³, C. Perez⁴, D.M. Miller⁵, J. Powderly⁶, A. Bessudo⁷, K. Montazeri⁸, M. Mooradian⁹, A. Gupta¹⁰, E. Patel¹⁰, D. Fantini¹⁰, S. Paramasivan¹⁰, D. Crowe¹⁰, M. Duncan¹⁰, S. Uptain¹¹, K. Luptakova¹⁰, R. Sullivan⁵, ¹University of Pittsburgh Cancer Institute, Pittsburgh, United States of America, ²Tranquile Clinical Research, Webster, United States of America, ³NEXT Oncology, San Antonio, United States of America, ⁴Florida Cancer Specialists and Sarah Cannon Research Institute, Orlando, United States of America, ⁵Mass General Cancer Center: Hematology Oncology, Boston, United States of America, ⁶Carolina BioOncology Institute, Huntersville, United States of America, ⁷California Cancer Associates for Research and Excellence, cCARE, Encinitas, United States of America, ⁸Massachusetts

General Hospital Cancer Center, Harvard Medical School, Boston, United States of America, ⁹Massachusetts General Hospital Cancer Center, Boston, United States of America, ¹⁰Xilio Therapeutics, Inc., Waltham, United States of America, ¹¹Xilio Therapeutics, Waltham, United States of America

- 05:00 - 05:00 **134P - A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors**
David Pinato¹, U. Banerji², S. Rottey³, K. Peltola⁴, J. Yachnin⁵, R. Kristeleit⁶, M. Gutierrez⁷, S. Symeonides⁸, N. Jebsen⁹, M. Hoejgaard¹⁰, W. Edenfield¹¹, K. Smeland¹², A. Schiza¹³, L. Ny¹⁴, V. Ebian¹⁵, J. Daniel¹⁵, J. Pulini¹⁵, R. Plummer¹⁶, ¹Imperial College London - Hammersmith Hospital, London, United Kingdom, ²The Royal Marsden Hospital NHS Trust, Sutton, United Kingdom, ³Ghent University Hospital, Gent, Belgium, ⁴HUS Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland, ⁵Karolinska University Hospital, Solna, Sweden, ⁶Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷Hackensack University Medical Center, Hackensack, United States of America, ⁸University of Edinburgh, Edinburgh, United Kingdom, ⁹Haukeland University Hospital, Bergen, Norway, ¹⁰Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark, ¹¹Prisma Health Cancer Institute - Faris, Greenville, United States of America, ¹²Oslo University Hospital, Oslo, Norway, ¹³Uppsala Universitet - Akademiska Sjukhuset, Uppsala, Sweden, ¹⁴Sahlgrenska University Hospital, Göteborg, Sweden, ¹⁵Incyte Corporation, Wilmington, United States of America, ¹⁶Newcastle Hospital NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom
- 05:00 - 05:00 **135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial**
Carlos Becerra¹, H. Olivecrona², M. De Château³, S.A. Paulson⁴, ¹Baylor University Medical Center (part of Baylor Scott & White Health), Dallas, United States of America, ²Baylor Scott & White Research Institute, Dallas, United States of America, ³Buzzard Pharmaceuticals AB, Stockholm, Sweden, ⁴Baylor University Medical Center (Baylor University Medical Center, part of Baylor Scott & White Health), Dallas, United States of America
- 05:00 - 05:00 **136P - Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostic treatment to harmonize resistant TFG-Beta stromal microenvironment in conjunction with PDL-1 based immunotherapy in disseminated cancers-Concept randomised study.**
G Lohith¹, K. Sekar², K. Kallur², S. Bj², S. Chiradoni Thungappa², R. Thippeswamy³, M. Naseer R³, S. Swamy³, S. Patil³, A. Bs², ¹HCG Cancer Center, Gulbarga, India, ²HCG HealthCare Global Enterprises Ltd, Bangalore, India, ³HCG Cancer Center, bengaluru, India
- 05:00 - 05:00 **137P - First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors**
Stephane Champiat¹, A. Italiano², N. Wagle³, U. Lauer⁴, A.-M. Quinson⁵, S. Luecke⁶, V. Hern⁷, M. Porosnicu⁸, ¹Institut Gustave Roussy, Villejuif, France, ²Institute Bergonié, Bordeaux, France, ³Saint John's Cancer Institute, Santa Monica, United States of America, ⁴University Hospital Tübingen, Tübingen, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Tübingen, Germany,

⁵Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, United States of America, ⁶Boehringer Ingelheim International GmbH, Biberach an der Riß, Germany, ⁷Boehringer Ingelheim Ltd, Bracknell, United Kingdom, ⁸Wake Forest School of Medicine, Winston-Salem, United States of America

- 05:00 - 05:00 **138P - Generation of frameshift mutated TGF_{R2}-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF**
- Else Inderberg¹, S. Arbe-Barnes², J.A. Eriksen², B. Iverson², H. Kvalheim Eriksen², R. Miller³, K. Risberg Handeland², H. Vidarsdotter Juul¹, N. Singh⁴, ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway, ²Hubro Therapeutics AS - Radforsk, Oslo, Norway, ³Artemida Pharma Limited, Radlett, United Kingdom, ⁴Quotient Sciences, Nottingham, United Kingdom
- 05:00 - 05:00 **139P - Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase 1 study**
- Alexander Starodub¹, M. Opyrchal², R. Balaraman³, M. Barve⁴, D. Fei⁵, R. Li⁵, T. Bai⁵, L. Kong⁵, X. Qin⁵, C. Qin⁵, A.-R. Naqash⁶, ¹The Christ Hospital - Hematology & Oncology, Cincinnati, United States of America, ²Indiana University, Indianapolis, United States of America, ³Florida Cancer Affiliates, Ocala, United States of America, ⁴Mary Crowley Cancer Research Center, Dallas, United States of America, ⁵LaNova Medicines, Shanghai, China, ⁶Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City, United States of America
- 05:00 - 05:00 **140P - Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform**
- Elli Sandberg¹, J. Verdi², N. Papavasiliou¹, ¹DKFZ - German Cancer Research Center, Heidelberg, Germany, ²Panosome GmbH, Heidelberg, Germany
- 05:00 - 05:00 **141P - An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4**
- Lais Cristina Palhares, J. Chauhan, M. Grandits, P. Romero-Clavijo, R. Gitsaki-Taylor, S. Mele, S. Karagiannis, H. Bax, KCL - King's College London, London, United Kingdom
- 05:00 - 05:00 **142P - Identifying novel immunotherapy targets using machine learning and ex vivo validation**
- Marcellus Augustine¹, N. Rocha Nene², K. Thakkar², D. Qian², E. Fitzsimons², B. Simpson², C. Watkins³, C. Swanton⁴, K. Litchfield², ¹UCL - University College London, London, United Kingdom, ²UCL Cancer Institute - UCL - London's Global University, London, United Kingdom, ³Royal Holloway, University of London, London, United Kingdom, ⁴Francis Crick Institute, London, United Kingdom
- 05:00 - 05:00 **143P - Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594**
- Ann White¹, R. Mcelhone², C. Thompson², G. Le Friec², C. Berteau², T. Colley², V. O'Dowd², ¹UCB Celltech Ltd., Slough, United Kingdom, ²UCB Pharma, Slough, United

Kingdom

- 05:00 - 05:00 **144P - Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer**
Simon Döhrmann, J. Levin, N. Dedeic, A. Almaguer, D. Zuill, E. Abelovski, J. Fortier, Q. Zhao, M. Hernandez, K. Amundson, M. Moniz, H. Chen, D. Panickar, T. Lam, T. Brady, A. Borchardt, J.N. Cole, L. Tari, Cidara Therapeutics, Inc., San Diego, United States of America
- 05:00 - 05:00 **145P - An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles**
Zong Sean Juo¹, J.-T. Wang², C.-L. Tseng², H.-F. Teng², P.-H. Kuo², Y.-C. Cheng², Y.-J. Chen², Y.-H. Lu², T.-K. Shen², H.-F. Wang², P.-L. Tsai², Y.-C. Wu², C.-H. Ho², W.-T. Sun², Y.-C. Li², Y.-H. Lee², ¹HanchorBio Inc, Taipei City, Taiwan, ²HanchoBio Inc., Taipei, Taiwan
- 05:00 - 05:00 **130P - A Phase I Study of a Novel BCMA_CD3 Bispecific Antibody EMB-06 in Relapsed or Refractory Multiple Myeloma (RRMM)**
Peter Thian Guan Tan¹, S.J. Shavaksha², H.M. Prince³, Q. Yin⁴, C. Li⁵, Z. Cai⁶, L. Bao⁷, H. Jing⁸, P. Lai⁹, Q. Deng¹⁰, M. Zhang¹⁰, S. Zeng¹⁰, Q. Lu¹⁰, C. Jiang¹⁰, D. Wu¹¹, F. Ren¹⁰, J. Mi¹², ¹One clinical research, Nedlands, Australia, ²Sunshine Coast Haematology and Oncology Clinic, Buderim, Australia, ³Epworth Centre - Richmond, Richmond, Australia, ⁴Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, ⁵Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Chibi City, China, ⁶The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, China, ⁷Beijing Jishuitan Hospital - Xijiekou Branch, Beijing, China, ⁸Peking University Third Hospital, Beijing, China, ⁹Guangdong Provincial People's Hospital, Guangzhou, China, ¹⁰Shanghai EpimAb Biotherapeutics Co., Ltd., Shanghai, China, ¹¹EpimAb Biotherapeutics, Shanghai, China, ¹²Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 05:00 - 05:00 **146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses**
David Pejoski¹, C. Suess², A. Gouiller², M. Héritier², M. Boujut², S. Tardy², T. De Smedt², L. Galibert², W. Reith², M. Joerger³, C. Toso⁴, T. Kössler⁴, H. Hamed², L. Scapozza², ¹UNIGE - University of Geneva - Faculty of Medicine, Geneva, Switzerland, ²University of Geneva, Geneva, Switzerland, ³Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴HUG - Hopitaux Universitaires de Geneve, Geneva, Switzerland
- 05:00 - 05:00 **147P - Pre-clinical evaluation and safety profile of the highly selective anti-VISTA antibody K01401-020**
Geneviève Gueguen Dorbes, N. Loukili, A. Petain, J. Labbe, N. Boute, B. Akla, M. Broussas, P. Ferre, F. Hofmann, Pierre Fabre Laboratories, Toulouse, France
- 05:00 - 05:00 **148P - HexaBody-OX40, a novel Fc_ receptor crosslinking-independent OX40-targeting antibody, exhibits agonistic activity in vitro and antitumor activity in vivo**
Kristel Kemper¹, M. Köhne², M. Van Der Kroef¹, K.B. Nuermberger², M. Russier¹, G. Zom¹, A.-L. Krause², P. De Goeje¹, F. Gieseke², A. Gorlani¹, A. Muik², L. Guelen¹, D. Satijn¹, S. Fellermeier-Kopf², T. Ahmadi³, Ö. Türeci², E. Breij¹, U. Sahin², ¹Genmab BV,

Utrecht, Netherlands, ²BioNTech SE, Mainz, Germany, ³Genmab U.S., Inc., Plainsboro, United States of America

- 05:00 - 05:00 **149P - HLA/SIRPa bispecifics-A novel multitarget therapeutic strategy to induce potent anti-tumor immune responses**
Anahita Rafiei, I. Bengert, L. Kerr, J. Sigrist, C.L. Yang, M. Gualandi, A. Kumar, H. Ebersbach, S. Coats, O. Marroquin Belaunzaran, ImmunOs Therapeutics AG, Zurich, Switzerland
- 05:00 - 05:00 **150P - Chemotherapy in combination with Toll-like receptor agonism promoted antitumor immune response in triple negative breast cancer**
Eunice Dotse, L. King Hoo, M. Wang, C.Y. Tiu, Y. Li, K.T. Chow, City University of Hong Kong, Kowloon, Hong Kong PRC
- 05:00 - 05:00 **151P - Tumor organoid-derived TIL therapy for colorectal cancer**
Marc Leushacke, M. Pari, J. Ju, P.-Y. Lin, B. Shrestha, C. Chartier, NextVivo, Palo Alto, United States of America
- 05:00 - 05:00 **152P - Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are functional in high adenosine environment**
Nainesh Katagihallimath¹, S. Sharma², S. Venkatesan², R. Rao², N. Bharatham², M. Gupta², D. Kundu², H. Kaushik Kotakonda², R. Ramalingam Kalainesan², S. Reddy², B. Tewary², S. Muley³, A. Gangoli³, P. Chirapanda Uthappa³, L. Maitreyi², B. Venkatraman², S. Datta², S. V Rekha Sody², B. Majumder², S. Hameed P², ¹Bugworks Research India Pvt Ltd, Bengaluru, India, ²Bugworks Research India Pvt. Ltd., Bengaluru, India, ³Cytecare Cancer Hospitals, Bangalore, India
- 05:00 - 05:00 **153P - Discovery of a Novel, Dual CD73 and PD-1 Targeting Multispecific Drug Fc-Conjugate (DFC) for the Treatment of Cancer**
James Levin, S. Döhrmann, N. Dedeic, A. Almaguer, D. Zuill, E. Abelovski, J. Fortier, Q. Zhao, M. Hernandez, K. Amundson, M. Moniz, H. Chen, D. Panickar, T. Lam, T. Brady, A. Borchardt, J.N. Cole, G. Hough, J. Locke, L. Tari, Cidara Therapeutics, Inc., San Diego, United States of America
- 05:00 - 05:00 **154P - Computer-aided drug design based on CLDN4 ligand and its biological evaluation in ovarian cancer**
Yi Xu, Y. Shen, Southeast University - Dingjiaqiao Campus, Nanjing, China
- 05:00 - 05:00 **155P - A Phase 1 Study Exploring the Safety and Tolerability of the Small-Molecule PD-L1 Inhibitor INCB099280 in Select Advanced Solid Tumors**
Hans Prenen¹, T. Lesimple², M. Robert³, J.-P. Machiels⁴, B. Delafontaine⁵, P. Tomasini⁶, T. Meniawy⁷, N. Kotecki⁸, E. Van Cutsem⁹, S. Piha-Paul¹⁰, M. Schweizer¹¹, S. Gadgeel¹², S. Kondo¹³, K. Ouali¹⁴, Y. Kuboki¹⁵, J. Daniel¹⁶, V. Ebiana¹⁶, J. Howe¹⁶, S. Spitz¹⁶, A. Italiano¹⁷, ¹UZA - University Hospital Antwerp, Edegem, Belgium, ²Hopital Saint-Antoine, Paris, France, ³ARPEGO Network and Unicancer Group, ICO René Gauducheau Site, Saint-Herblain, France, ⁴Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, Belgium, ⁵UZ Ghent, Gent, Belgium, ⁶CEPCM, Aix Marseille University, Marseille, France, ⁷Linear Clinical Research and University of Western

Australia, Netherlands, Australia, ⁸Institut Jules Bordet, Brussels, Belgium, ⁹University Hospitals Gasthuisberg, Leuven & University of Leuven, Leuven, Belgium, ¹⁰University of Texas, MD Anderson Cancer Center, Houston, United States of America, ¹¹University of Washington and Fred Hutchinson Cancer Center, Seattle, United States of America, ¹²Henry Ford Cancer Institute/Henry Ford Health, Detroit, United States of America, ¹³National Cancer Center Hospital, Tokyo, Japan, ¹⁴Gustave Roussy, Villejuif, France, ¹⁵National Cancer Center Hospital East, Kashiwa, Japan, ¹⁶Incyte Corporation, Wilmington, United States of America, ¹⁷Institute Bergonié, Bordeaux, France

05:00 - 09:15

156TiP - The LUNGVAC-study; A randomized phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer (NSCLC)

Elin Marie Stensland, I.J.Z. Eide, O.T. Brustugun, Vestre Viken HF-Drammen sykehus, Drammen, Norway

09:15 - 13:30

157TiP - Krascendo-170 Lung: a phase Ib/II study of divarasisib + pembrolizumab _ platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)

Ferdinandos Skoulidis¹, K. Cuppens², A. Sacher³, V. Velcheti⁴, D.H. Lee⁵, M. Lin⁶, T. Fernando⁶, S. Li⁶, D. Bradley⁷, M. Zarak Crnkovic⁸, M. Mathisen⁶, ¹The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America, ²Jessa Hospital, Hasselt, Belgium, ³University of Toronto, Toronto, Canada, ⁴New York University Langone Health, New York, United States of America, ⁵University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of, ⁶Genentech, Inc., South San Francisco, United States of America, ⁷Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁸F. Hoffmann-La Roche Ltd, Basel, Switzerland

13:30 - 17:45

159TiP - Two Phase 1 Studies Assessing the Safety and Efficacy of the Small Molecule Oral PD-L1 Inhibitor INCB099280 in Combination with Adagrasib (INCB 99280-204 [Study 204]) or Ipilimumab (INCB 99280-205 [Study 205]) in Adults with Advanced Solid Tumors

David Berz¹, D. Pinato², M. Barve³, J. Pulini⁴, J. Bowman⁴, M. Johnson⁵, ¹Valkyrie Clinical Trials, Los Angeles, United States of America, ²Imperial College London - Hammersmith Hospital, London, United Kingdom, ³Mary Crowley Cancer Research Center, Dallas, United States of America, ⁴Incyte Corporation, Wilmington, United States of America, ⁵Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America

17:45 - 22:00

160TiP - Safety and Antitumor Activity of GEN1042 in Combination with Pembrolizumab _ Chemotherapy in Solid Tumors: Phase 2b Dose-Expansion Trial in Progress

Ignacio Melero¹, E. Grande², M. Johnson³, J. Bauman⁴, V. Moreno Garcia⁵, D. Adkins⁶, M.J. De Miguel⁷, D. Roda Perez⁸, S. Gattoni-Celli⁹, I. Celik¹⁰, J. Steinberg¹¹, T.J. Ong¹¹, E. Felip¹², ¹Clinica Universidad de Navarra, Pamplona, Spain, ²MD Anderson Cancer Center Madrid, Madrid, Spain, ³Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America, ⁴Fox Chase Cancer Center - Main Campus, Philadelphia, United States of America, ⁵Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain, ⁶Washington University School of Medicine in St. Louis, St. Louis, United States of America, ⁷CIOCC - Centro Integral Oncológico Clara Campal, Hospital

Universitario HM Sanchinarro, Madrid, Spain, ⁸Hospital Clinico Universitario de Valencia, Valencia, Spain, ⁹BioNTech US, Cambridge, United States of America, ¹⁰BioNtech SE, Mainz, Germany, ¹¹Genmab U.S., Inc., Plainsboro, United States of America, ¹²Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain

22:00 - 02:15 **161TiP - A Phase 1/2, Open-label Study of an Anti-ILT2 (LILRB1) Antibody, SAR444881, Administered Alone and in Combination With Pembrolizumab, With or Without Chemotherapy, or Cetuximab in Patients With Advanced Solid Tumors**

Ruth Perets¹, S. Stemmer², R. Geva³, T. Golan⁴, M. Fakhri⁵, J. Cohen⁶, C. Lieu⁷, Z. Jin⁸, P. Lorusso⁹, N. Ashtamker¹⁰, I. Friedman¹¹, M. Hakim¹⁰, N. Crawford¹², R. Perez¹², M. Agarwal¹³, G. Abbadessa¹³, M. Wu¹³, J. Lin¹³, C. Deantonio¹⁴, M. Borad¹⁵, ¹Rambam Medical Center, Haifa, Israel, ²Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, Israel, ³Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, Israel, ⁴Chaim Sheba Medical Center, Ramat Gan, Israel, ⁵City of Hope Comprehensive Cancer Center, Duarte, United States of America, ⁶Hadassah Cancer Research Institute, Jerusalem, Israel, ⁷University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, United States of America, ⁸Mayo Clinic, Rochester, United States of America, ⁹Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, United States of America, ¹⁰Biond Biologics Ltd, Misgav Industrial Park, Israel, ¹¹Biond Biologics Ltd, Misgav industrial park, Israel, ¹²Sanofi, Bridgewater, United States of America, ¹³Sanofi, Cambridge, United States of America, ¹⁴Sanofi UK, Cambridge, United Kingdom, ¹⁵Mayo Clinic Arizona, Scottsdale, United States of America

02:15 - 02:15 **164P - Disentangling the Joint and Distinct Immunomodulation and Vulnerability Between KEAP1/NFE2L2 and SMARCA4 Alterations in Lung Adenocarcinoma**

Anlin Li¹, L. Luo¹, W. Du¹, K. Wu², Z. Yan², Z. Yu¹, L. Zhang¹, S. Hong³, ¹Sun Yat-sen University Cancer Center, Guangzhou, China, ²Shantou University Medical College, Shantou, China, ³Sun Yat-sen University Cancer Center, Guangzhou, China

02:15 - 02:15 **165P - Immunosuppressive F13A1+ Mo/M₂ in the tumor microenvironment as a hallmark for multiple primary lung cancers**

Jiahao Qu¹, C. Yang¹, J. Wu¹, Z. Yu¹, Y. Meng², L. Zheng², L. Zhang², L. Wang², X. Guo¹, ¹Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, China, ²Hangzhou Repugene Technology Co.,Ltd., Hangzhou, China

02:15 - 02:15 **166P - Three-dimensional (3D) Innervation of Mouse Lungs and Airways in a Lung Metastatic Tumor Model**

Yan Zhou, H. Zhong, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

02:15 - 02:15 **158TiP - MK-3475A-D77 Study: Phase 3, Randomized, Open-Label Study of First-Line (1L) Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase vs Intravenous (IV) Pembrolizumab With Chemotherapy in Metastatic Squamous or Nonsquamous NSCLC**

Mehmet Ali Nahit Sendur¹, T. Takahashi², R. Eiras³, X. Deng³, M.C. Pietanza³, E. Felip⁴, ¹Ankara Yildirim Beyazit University - Faculty of Medicine, Ankara, Turkey, ²Shizuoka Cancer Center, Shizuoka, Japan, ³Merck & Co., Inc., Rahway, United States of America,

⁴Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain

- 02:15 - 02:15 **167P - Lurbinectedin, a DNA minor groove inhibitor launches a multimodal immune response through activation of the cytosolic DNA-Sensing cGAS-STING pathway.**
Triparna Sen, Memorial Sloan Kettering Cancer Center, New York, United States of America
- 02:15 - 02:15 **168P - Effect of sequence treatment of chemotherapy plus radiotherapy activates innate immunity in SCLC**
Caterina De Rosa, C. Tuccillo, L. Amato, F. Ciardiello, V. Nardone, F. Morgillo, C. Della Corte, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
- 02:15 - 02:15 **169P - High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer**
Angelica Rigutto¹, N. Nunez², J. Kienzler², M. Kirschner³, I. Opitz³, S. Hiltbrunner¹, N. Fournier⁴, J. Lourenço⁴, R. Gottardo⁴, B. Becher², A. Curioni-Fontecedro⁵, ¹University of Fribourg, Fribourg, Switzerland, ²University of Zürich, Zurich, Switzerland, ³University Hospital Zürich, Zurich, Switzerland, ⁴SIB - Swiss Institute of Bioinformatics, Lausanne, Switzerland, ⁵Cantonal Hospital Fribourg, Fribourg, Switzerland
- 02:15 - 02:15 **170P - Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)**
Nicholas Venturini, P. Hamon, S. Ward, M. Fiel, M. Beasley, E. Kim, K. Garcia-Reyes, U. Chaddha, T. Harkin, G. Gunasekaran, P. Tabrizian, D. Nicastri, D. Del Valle, C. Hennequin, S. Kim-Schulze, S. Gnjatic, M. Schwartz, A. Kaufman, M. Merad, T. Marron, Icahn School of Medicine at Mount Sinai, New York, United States of America
- 02:15 - 06:30 **162TiP - Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors**
Anthony Tolcher¹, N. Germann², S. Luecke³, M. Bailey⁴, ¹NEXT OncologyTM, San Antonio, United States of America, ²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ³Boehringer Ingelheim International GmbH, Biberach an der Riß, Germany, ⁴Boehringer Ingelheim Ltd, Berkshire, United Kingdom
- 06:30 - 06:30 **171P - Immune landscape and CLEVER-1 expression in hepatoblastoma**
Ville Väyrynen¹, K. Eloranta², M. Pihlajoki², J. Lohi³, A. Kyrönlähti², M. Hollmén⁴, S. Jalkanen⁵, M. Heikinheimo², ¹University of Helsinki, Helsinki, Finland, ²Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ³Helsinki University Central Hospital, Helsinki, Finland, ⁴University of Turku, Turku, Finland, ⁵University of Turku - Faculty of Medicine, Turku, Finland
- 06:30 - 06:30 **172P - PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment**

Ju Yang¹, S. He², Z. Zhou³, Y. Chen³, X. Cui⁴, ¹Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, nanjing, China, ²Hubei University of Medicine, Shiyan, China, ³The First Affiliated Hospital of Medical College Shihezi University, Shihezi, China, ⁴The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

06:30 - 06:30 **173P - Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer**

Job Saris¹, A. Li Yim¹, S. Bootsma², J. Verhoeff¹, J. Tuynman³, M. Wildenberg¹, G. D'Haens¹, R. Franco Fernandez¹, H. Khan¹, K. Lenos², J. Garcia Vallejo⁴, L. Vermeulen², J. Grootjans¹, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Amsterdam UMC, locatie VUmc, Amsterdam, Netherlands, ⁴Molecular Cell Biology & Immunology, Amsterdam, Netherlands

06:30 - 06:30 **174P - Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity**

Yizhi Zhan, Z. Shen, G. Li, Y. Fang, Southern Medical University Nanfang Hospital, Guangzhou, China

06:30 - 06:30 **175P - MicroRNA-548c: An Immune-Activator microRNA at the Tumor Microenvironment and Immune Milieu of Breast Cancer**

Alyaa Dawoud¹, R.A. Youness², H. Nafea¹, C. Bourquin³, C. Szabo⁴, R. Abdel-Kader¹, M. Gad¹, ¹GUC - German University in Cairo, New Cairo, Egypt, ²German International University (GIU), Cairo, Egypt, ³UNIGE - Université de Genève - Centre Médical Universitaire (CMU), Geneva, Switzerland, ⁴University of Fribourg, Fribourg, Switzerland

06:30 - 06:30 **176P - Multiplex-immunofluorescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study**

Andrea Joaquin Garcia¹, J. Krawczyk², M. Rediti¹, K. Gogolewski², M. Mozejko², S. Tissot³, S. Rusakiewicz³, L. Despland⁴, M. Morfouace⁵, R. Liechti⁶, F. Marzetta⁶, X. Wang¹, D. Vincent¹, J.-C. Goeminne⁷, J. Oliveira⁸, H. Hong⁹, M. Cesaroni¹⁰, C. Sotiriou¹, E. Szczurek², L. Buisseret¹, ¹Institute Jules Bordet, Brussels, Belgium, ²University of Warsaw, Warsaw, Poland, ³Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, Switzerland, ⁴CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁵Merck KGaA - Headquarters Merck Group, Darmstadt, Germany, ⁶SIB - Swiss Institute of Bioinformatics, Lausanne, Switzerland, ⁷CHU-UCL-Namur - Site Sainte-Elisabeth, Namur, Belgium, ⁸Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (IPO-Porto), Porto, Portugal, ⁹Merck KGaA, Darmstadt, Germany, ¹⁰Sanofi - France, Paris, France

06:30 - 06:30 **177P - The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling**

Bhawna Deswal, U. Bagchi, S. Kapoor, Amity University, Noida, India

- 06:30 - 06:30 **178P - Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy / immunotherapy.**
Charlotte Birchall¹, A. Merhi², A. Devaux³, I. Bar², S. Haussy², D. Petrone², G. Beniuga², P. Delree², J.-L. Canon⁴, M. Devos⁵, F. Duhoux¹, J. Carrasco³, ¹Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, Belgium, ²IPG - Institut de Pathologie et de Genetique, Gosselies, Belgium, ³Grand Hopital de Charleroi (GHdC), Charleroi, Belgium, ⁴GHdC - Grand Hopital de Charleroi - Site Notre Dame, Charleroi, Belgium, ⁵Seqalis (IPG Group), Charleroi, Belgium
- 06:30 - 06:30 **179P - Integrating multiplex immunofluorescence with gene expression data in the IMMUCan HER2-positive breast cancer cohort**
Mattia Rediti¹, A. Joaquin Garcia¹, S. Tissot², S. Rusakiewicz², L. Despland³, M. Morfouace⁴, R. Liechti⁵, F. Marzetta⁵, J. Oliveira⁶, J.-C. Goeminne⁷, A. Capela Marques⁸, L. Greillier⁹, X. Wang¹⁰, D. Vincent¹⁰, H. Hong¹¹, M. Cesaroni¹², C. Sotiriou¹, L. Buisseret¹, ¹Institute Jules Bordet, Brussels, Belgium, ²Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, Switzerland, ³CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁴Merck KGaA - Headquarters Merck Group, Darmstadt, Germany, ⁵SIB - Swiss Institute of Bioinformatics, Lausanne, Switzerland, ⁶Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (IPO-Porto), Porto, Portugal, ⁷CHU-UCL-Namur - Site Sainte-Elisabeth, Namur, Belgium, ⁸CHVNG/E - Centro Hospitalar de Vila Nova de Gaia/Espinho - Unidade 1 - EPE-SNS, Vila Nova de Gaia, Portugal, ⁹Assistance Publique-Hôpitaux de Marseille, Aix Marseille University, Marseille, France, ¹⁰Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium, ¹¹Merck KGaA, Darmstadt, Germany, ¹²Sanofi - France, Paris, France
- 06:30 - 06:30 **180P - Immunogenomic profiling of the randomized NeoPembrOv clinical trial reveals the VEGFR2 angiogenic axis as a promising actionable target to overcome immunoresistance of high-grade ovarian carcinomas**
Olivia Le Saux¹, M. Ardin², J. Berthet², M. Bourhis³, I. Treilleux¹, P.-A. Just⁴, G. Bataillon⁵, A.M. Savoye⁶, M.-A. Mouret-Reynier⁷, E. Coquan⁸, O. Derbel⁹, S. Bouizaguen¹⁰, S.I. Labidi-Galy¹¹, E. Tartour¹², I. Galy-Fauroux¹³, M.-H. Stern¹⁴, M. Terme³, C. Caux¹⁵, B. Dubois², I. Ray-Coquard¹, ¹Centre Léon Bérard, Lyon, France, ²CRCL - Centre de recherche en cancerologie de Lyon, Lyon, Cedex, France, ³INSERM UMR 970 - Paris Centre de Recherche Cardiovasculaire (PARCC), Paris, France, ⁴AP-HM - CHU La Timone Enfants, Marseille, France, ⁵IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France, ⁶CHU de Reims - Hôpital Robert Debré, Reims, Cedex, France, ⁷Centre Jean-Perrin, Clermont-Ferrand, France, ⁸Centre Francois Baclesse, Caen, Cedex, France, ⁹Cabinet Medical, Lyon, France, ¹⁰Tribun Health, Paris, France, ¹¹HUG - Hopitaux Universitaires de Geneve, Geneva, Switzerland, ¹²HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, France, ¹³Université René Descartes, Paris, France, ¹⁴Institut Curie, Paris, France, ¹⁵Centre de recherche en cancerologie de Lyon (CRCL), Lyon, France
- 06:30 - 06:30 **181P - Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer**
Jitka Palich Fucikova, L. Kasikova, M. Hensler, R. Spisek, SOTIO Biotech a.s., Prague, Czech Republic

- 06:30 - 06:30 **182P - Exploring Cross-Compartmental Tumor Cell Plasticity and Immunogenicity in Serous Ovarian Cancer**
Louisa Hell¹, T. Sturmheit², L. Oliveira-Ferrer³, Y. Ding³, C. Pellens³, K. Eylmann³, M. Rossberg³, W. Fiedler³, J. Kupper², B. Schmalfeldt³, F. Brauneck³, J. Wellbrock³,
¹University medical center Hamburg-Eppendorf, Hamburg, Germany, ²cureX GmbH, Hamburg, Germany, ³University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 06:30 - 06:30 **183P - Multi-omics Investigation Reveals Cancer-Associated Fibroblast-Secreted FGF7 as an Ovarian Cancer Progression Promoter through HIF-1_α/EMT Modulation**
Songwei Feng, Southeast University - Dingjiaqiao Campus, Nanjing, China
- 06:30 - 06:30 **184P - Elevated baseline circulating IL-8 is associated with increased expression of the IMmotion myeloid gene signature (GS) in metastatic clear cell renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo) within the NIVOREN GETUG-AFU 26 study.**
Lucia Carril Ajuria¹, R. Flippot¹, C. Dalban², A. Desnoyer³, N. Rioux-Leclercq⁴, C. Sautes-Fridman⁵, M. Meylan⁶, Y. Vano⁷, B. Beuselinck⁸, S. Chouaib⁹, C. De Oliveira⁹, F. Tantot¹⁰, B. Escudier¹, N. Chaput-Gras⁹, L. Albiges⁹, L. Carril Ajuria¹, ¹Institut Gustave Roussy, Villejuif, France, ²Centre Leon Berard, Lyon, France, ³Gustave Roussy - Cancer Campus, Villejuif, France, ⁴CHU de Rennes - Hopital Pontchaillou, Rennes, Cedex, France, ⁵Centre de Recherche des Cordeliers, Paris, France, ⁶Dana Farber Cancer Institute, Boston, United States of America, ⁷HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, France, ⁸University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium, ⁹Institut Gustave Roussy, Villejuif, Cedex, France, ¹⁰Unicancer, Paris, Cedex, France
- 06:30 - 06:30 **185P - The Immunosuppressive Landscape of Leukemia Inhibitory Factor (LIF) in Clear Cell Renal Cell Carcinoma**
Yazan Al Zu'Bi¹, S. Al Sharie², J. Al Ajlouny¹, O. Al Kilani¹, A. Faddah¹, L. Quran¹, S. Bashammakh¹, A. Al Sharie¹, ¹JUST - Jordan University of Science and Technology, Irbid, Jordan, ²Yarmouk University, Irbid, Jordan
- 06:30 - 06:30 **186P - Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: an EORTC IMMUCan sub-project**
Athénaïs Van Der Elst¹, D. Herrero Saboya², L. Michon³, M. Morfouace⁴, R. Liechti⁵, D. Schulz⁶, P. Devanand⁷, R. Galot⁸, A. Essabar⁹, V. Pancaldi⁹, J. Merlevede¹⁰, H. Hong¹¹, L. Martignetti¹², C. Lefebvre¹³, C. Even¹⁴, C. Le Tourneau¹², A. Daste¹⁵, S. Lucas¹⁶, P. Saintigny¹⁷, J.-P. Machiels⁸, ¹UCLouvain Brussels Woluwe, Brussels, Belgium, ²Institut Curie; Servier Research & Development, Paris, France, ³Center Leon Berard, Lyon, France, ⁴Merck KGaA - Headquarters Merck Group, Darmstadt, Germany, ⁵SIB - Swiss Institute of Bioinformatics, Lausanne, Switzerland, ⁶UZH - University of Zurich - Irchel Campus, Zurich, Switzerland, ⁷Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, Switzerland, ⁸Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, Belgium, ⁹CRCT - Centre de Recherches en Cancérologie de Toulouse, Toulouse, France, ¹⁰Institut Curie; INSERM U900; Mines ParisTech, Paris, France, ¹¹Merck KGaA, Darmstadt, Germany, ¹²Institut Curie, Paris, France, ¹³Servier Research & Development, Saclay, France, ¹⁴Institut Gustave Roussy, Villejuif, France,

¹⁵CHU Bordeaux - Hopital St. André, Bordeaux, France, ¹⁶De Duve Institute UCLouvain, Woluwe-Saint-Lambert, Belgium, ¹⁷Centre Léon Bérard, Lyon, France

06:30 - 06:30 **187P - Local and systemic anti-tumor response during tumor development in an immune privileged site: the case of uveal melanoma**

Francesca Lucibello¹, A.I. Lalanne¹, A.-L. Le Gac¹, A. Soumare¹, S. Gardrat¹, N. Cassoux², G. Pierron¹, S. Piperno-Neumann¹, M.-H. Stern¹, M. Rodrigues¹, O. Lantz¹, ¹Institut Curie, Paris, France, ²Université Paris Cité, Paris, France

06:30 - 06:30 **188P - Expression of the co-stimulatory checkpoint protein OX40L (TNFSF4) in the melanoma micro-environment**

Raya Leibowitz-Amit¹, S. Feldman², B. Daana¹, L. Elkis², S. Mendelovic¹, A. Avraham¹, ¹Yizhak Shamir Medical Center - Assaf HaRofeh Campus, Be'er-Yaakov, Israel, ²Yizhak Shamir Medical Center - Assaf HaRofeh Campus, Beer Yaakov, Israel

06:30 - 06:30 **189P - The impact of immune microenvironment subpopulations on soft tissue sarcomas**

Shokhrukhbek Khujaev¹, D. Polatova¹, N. Karimova¹, S. Sheralieva¹, D. Rasulbek Rakhimberdiyevich², I. Abdulazizovna³, N. Asamedinov¹, ¹Tashkent State Dental Institute, Tashkent, Uzbekistan, ²Republican Specialized Scientific-Practical Medical Center of Oncology and Radiology, Urgench, Uzbekistan, ³Tashkent Medical Academy, Tashkent, Uzbekistan

06:30 - 06:30 **190P - Immune-related roles of B7H3 in glioblastoma**

Arnaud Simonet¹, V. Neirinckx², G. Jerusalem³, B. Rogister², ¹CHU de Liège - Sart Tilman Site, Liège, Belgium, ²Université de Liège, Liège, Belgium, ³Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium

06:30 - 06:30 **191P - Senolytic treatment remodels glioblastoma microenvironment**

Alexa Saliou, J. Guegan, I. Le Roux, Paris Brain Institute, Paris, France

06:30 - 06:30 **192P - Analysis of Tumor-Associated Macrophages and Tumor-infiltrating Lymphocytes within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases**

Markus Kleinberger¹, D. Cifci², C. Paiato³, E. Tomasich³, M. Mair³, A. Steindl³, Z. Carrero⁴, L. Berchtold³, J. Hainfellner⁵, L. Müllauer⁵, G. Heller³, M. Preusser³, J. Kather⁶, A.S. Berghoff³, ¹MedUni Wien - Medical University of Vienna, Vienna, Austria, ²Dresden University, Dresden, Germany, ³Universitätskliniken der MedUni Wien - AKH Wien, Vienna, Austria, ⁴Technische Universität Dresden, Dresden, Germany, ⁵Medical University Vienna, Vienna, Austria, ⁶Technische Universität Dresden - Carl Gustav Carus Faculty of Medicine, Dresden, Germany

06:30 - 06:30 **193P - Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibit anti-cancer immunity via CCL2**

Ronja Wieboldt¹, E. Carlini¹, C.-W. Lin², A. Börsch¹, A. Zingg¹, A. Zippelius³, H. Läubli³, N. Rodrigues Mantuano⁴, ¹University of Basel - Department of Biomedicine, Basel, Switzerland, ²Functional Genomics Center Zurich, ETH Zurich, Zurich, Switzerland,

³University Hospital Basel, Basel, Switzerland, ⁴Universitätsspital Basel, Basel, Switzerland

- 06:30 - 06:30 **194P - Achieving Reproducible Maturation Staging of Tertiary Lymphoid Structures: from Imaging Mass Cytometry Data to Pathology Applications**
Marion Le Rochais, S. Garaud, P. Hemon, A. Uguen, CHRU Brest - Hopital Augustin Morvan, Brest, France
- 06:30 - 06:30 **195P - IMMUcan - Toward a better understanding of the tumor microenvironment to inform precision oncology approaches.**
Marie Morfouace¹, L. Buisseret², B. Besse³, J.-P. Machiels⁴, C. Sotiriou², M.-S. Robert⁵, D. Schaer⁶, S. Rusakiewicz⁷, D. Schulz⁸, B. Fournier⁵, H. Hong⁹, R. Liechti¹⁰, ¹Merck KGaA - Headquarters Merck Group, Darmstadt, Germany, ²Institute Jules Bordet, Brussels, Belgium, ³Institut Gustave Roussy, Villejuif, France, ⁴Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, Belgium, ⁵EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, Belgium, ⁶Bayer Pharmaceuticals, Cambridge, United States of America, ⁷Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, Switzerland, ⁸UZH - University of Zurich - Irchel Campus, Zurich, Switzerland, ⁹Merck KGaA, Darmstadt, Germany, ¹⁰SIB - Swiss Institute of Bioinformatics, Lausanne, Switzerland
- 06:30 - 06:30 **196P - Local glycan engineering induces systemic antitumor immune reactions via antigen cross-presentation**
Natalia Rodrigues Mantuano¹, M. Sandholzer², F. Filipisky², A. Zingg², R. Wieboldt², A. Zippelius³, H. Läubli³, ¹Universitätsspital Basel, Basel, Switzerland, ²University of Basel - Department of Biomedicine, Basel, Switzerland, ³University Hospital Basel, Basel, Switzerland
- 06:30 - 06:30 **197P - Computational pathology pipeline enables quantification of intratumor heterogeneity and tumor-infiltrating lymphocyte score**
Daniel Tiezzi¹, A. Fröhlich², F. Chahud³, S. Pagnota⁴, ¹HC-FMRP-USP - Hospital das Clínicas da Faculdade de Medicina de Ribeirao, Ribeirao Preto, Brazil, ²Federal University of Santa Catarina UFSC, Araranguá, Brazil, ³Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, Brazil, ⁴University of Sannio RCOST, Benevento, Italy
- 06:30 - 06:30 **198P - Polarization of tumor-associated macrophages enhanced by 2-HP-_-cyclodextrin modified PLGA nanoparticles**
Hao Yuan¹, H. Gui², L.Z. Li³, ¹Guizhou University, GUI YANG, China, ²Guizhou Provincial People's Hospital, Guiyang, China, ³Guizhou University, Guiyang, China
- 06:30 - 06:30 **199P - Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium**
Nils Eling¹, J. Dorier², S. Rusakiewicz³, S. Tissot³, P. Devanand³, M. Daniel⁴, S. Déglise⁴, B. Palau Fernandez⁴, J. Windhager⁴, M. Mozejko⁵, K. Gogolewski⁵, J. Krawczyk⁵, A. Essabbar⁶, V. Pancaldi⁶, E. Szczurek⁵, M. Morfouace⁷, H. Hong⁸, R. Liechti⁹, B. Bodenmiller⁴, D. Schulz¹⁰, ¹UZH - University of Zurich - Competence Center Personalized Medicine (CC-PM), Zurich, Switzerland, ²UNIL - University of Lausanne,

Lausanne, Switzerland, ³Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, Switzerland, ⁴University of Zurich, Zurich, Switzerland, ⁵University of Warsaw, Warsaw, Poland, ⁶CRCT - Centre de Recherches en Cancérologie de Toulouse, Toulouse, France, ⁷Merck KGaA - Headquarters Merck Group, Darmstadt, Germany, ⁸Merck KGaA, Darmstadt, Germany, ⁹SIB - Swiss Institute of Bioinformatics, Lausanne, Switzerland, ¹⁰UZH - University of Zurich - Irchel Campus, Zurich, Switzerland

- 06:30 - 06:30 **200P - A novel multi-organ on chip model for metastatic tumor biology understanding**
Elisabetta Palama¹, M. Aiello¹, S. Scaglione², ¹React4life Srl, Genova, Italy, ²CNR, Genova, Italy
- 06:30 - 06:30 **201P - Role of aerobic exercise training on the mitochondrial metabolism and effector function of CD8+ tumor-infiltrating lymphocytes**
Janaina Vieira¹, V. Voltarelli², M. Amano³, A. Camargo⁴, P. Brum¹, ¹USP - Universidade de Sao Paulo, Sao Paulo, Brazil, ²Harvard Medical School, Boston, United States of America, ³Instituto Sirio-Libanês de Ensino e Pesquisa, Sao Paulo, Brazil, ⁴Hospital Sirio Libanês - Complexo Hospitalar Bela Vista, Sao Paulo, Brazil
- 06:30 - 06:30 **202P - Discovery of immunological cellular neighborhoods from protein markers in spatial tumor data**
Marcin Mozejko¹, K. Gogolewski¹, D. Schulz², N. Eling³, J. Krawczyk¹, A. Mozwillo¹, M. Daniel⁴, E. Staub⁵, M. Mourface⁵, H. Hong⁶, B. Bodenmiller⁴, E. Szczurek¹, ¹University of Warsaw, Warsaw, Poland, ²UZH - University of Zurich - Irchel Campus, Zurich, Switzerland, ³UZH - University of Zurich - Competence Center Personalized Medicine (CC-PM), Zurich, Switzerland, ⁴University of Zurich, Zurich, Switzerland, ⁵Merck KGaA - Headquarters Merck Group, Darmstadt, Germany, ⁶Merck KGaA, Darmstadt, Germany
- 06:30 - 06:30 **203P - Identification of High Confidence Candidate Markers for Macrophage Infiltrating Tumor Microenvironment through Single Cell Genomic Atlases**
Constance Ciaudo Beyer, Nebion AG, Zurich, Switzerland
- 06:30 - 06:30 **204P - Effect of STAT6 Inhibition as a Novel Strategy for Promoting the Induction of Potent and Stable Regulatory T Cells for Use in Colitis Therapy**
Sonia Leon-Cabrera, F. Perez-Noriega, M.F. Correa Perez, R. Arroyo-Olarte, UNAM - Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, Mexico
- 06:30 - 06:30 **125P - Efficacy and safety of the therapeutic DNA vaccine VB10.16 in combination with atezolizumab in advanced HPV16-positive cervical cancer: Updated analysis from the VB-C-02 trial**
Kristina Lindemann¹, R. Oliveri², ¹Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway, ²Nykode Therapeutics Denmark A/S, Kongens Lyngby, Denmark
- 06:30 - 06:30 **87P - Real-world analysis of atezolizumab in ES-SCLC patients and those with brain metastases: An improved survival outcome**
Minglei Zhuo¹, Y. He¹, H. Chen¹, X. Ma¹, J. Liu², Y. Yang³, Y. Fang⁴, L. Wang⁵, J. Fang¹, J. Zhao⁶, ¹Peking University Cancer Hospital & Institute, Beijing, China, ²Public Health

Clinical Center Affiliated to Shandong University, Shandong University, Jinan, China, ³The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China, ⁴Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China, ⁵Baotou Cancer Hospital, Baotou, China, ⁶Peking University Cancer Hospital and Institute, Beijing, China

06:30 - 06:30 **2P - Beyond PD-L1: unraveling the enigma of immunotherapy response in PD-L1 negative NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumour microenvironment.**

James Miles¹, J. Gumuzio², V. Calleja², ¹HAWK Biosystems, Bilbao, Spain, ²HAWK Biosystems, Derio, Spain

06:30 - 06:30 **8P - Exploration of Potential Biomarkers Correlated with Efficacy of Ociperlimab (OCI) plus Tislelizumab (TIS) in 1L PD-L1+ Non-Small Cell Lung Cancer (NSCLC)**

Se Hyun Kim¹, J. Zhang², W. Tan², H. Yan³, T. Tian³, H. Zheng⁴, Z. Zhou², R. Wang², Y. Zhang³, Z. Shen³, H.R. Kim⁵, D. Zhong⁶, S. Lu⁷, ¹Seoul National University Bundang Hospital, Seongnam, Korea, Democratic People's Republic of, ²BeiGene (Shanghai) Co., Ltd., Shanghai, China, ³BeiGene (Beijing) Co., Ltd., Beijing, China, ⁴BeiGene, Ltd., San Mateo, United States of America, ⁵Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, ⁶Tianjin Medical University General Hospital, Tianjin, China, ⁷Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

13:00 - 14:00	Type: ESMO Colloquium Title: ESMO Colloquium supported by Novocure: Therapeutic applications and synergies of electric fields in oncology Moderation: Alessandra Curioni-Fontecedro, Switzerland; Andreas Hottinger, Switzerland	Room A
13:00 - 13:02	Welcome and introduction <u>Alessandra Curioni-Fontecedro</u> , Cantonal Hospital Fribourg, Fribourg, Switzerland	
13:02 - 13:17	Preclinical evidence for mechanism of action and synergistic cancer cytotoxicity of electric fields with the modulation of the host immune system <u>Andreas Hottinger</u> , Lausanne, Switzerland	
13:17 - 13:32	Clinical evidence for efficacy & safety of electric fields as monotherapy and in combination with other targeted and immunomodulatory therapies in solid tumours <u>Alessandra Curioni-Fontecedro</u> , Cantonal Hospital Fribourg, Fribourg, Switzerland	
13:32 - 13:47	Research insights in future developments of electric field applications in oncology and potential for combination with IO approaches <u>Teresa Macarulla Mercade</u> , Vall d'Hebron Institute of Oncology, Vall d'Hebrón University Hospital, Barcelona, Spain	
13:47 - 13:57	Q&A and discussion <u>All Speakers</u> , Geneva, Switzerland	
13:57 - 14:00	Concluding remarks <u>Andreas Hottinger</u> , Lausanne, Switzerland	
13:15 - 14:00	Type: Young Oncologists (YO) session Title: YO Mentorship 1 Moderation: Maria Kfoury, France; Angelika Starzer, Austria; Kok Haw Jonathan Lim, United Kingdom	Room K
13:15 - 14:00	Immunotherapy in rare tumours and hard to treat cancers: Untapped opportunities or impossible challenge? <u>Ignacio Melero</u> , Clinica Universidad de Navarra, Pamplona, Spain	

13:15 - 14:00 **Type: Young Oncologists (YO) session** **Room K**
Title: YO Mentorship 2
 Moderation: Kok Haw Jonathan Lim, United Kingdom; Maria Kfoury, France; Angelika Starzer, Austria

13:15 - 14:00 **How to keep up to date in the fast evolving field of immunotherapy**
Jarushka Naidoo, Beaumont Hospital, Dublin, Ireland

14:15 - 15:15 **Type: Controversy session** **Room A**
Title: Is TMB a good predictive biomarker for immunotherapy?
 Moderation: Aurelien Marabelle, France

14:15 - 14:25 **Introduction and first vote**
Aurelien Marabelle, Institut Gustave Roussy, Villejuif, France

14:25 - 14:45 **Yes**
Francois Ghiringhelli, Centre Georges-François Leclerc (Dijon), Dijon, France

14:45 - 15:05 **No**
Benoit Rousseau, MSKCC - Memorial Sloan Kettering Cancer Center, New York, United States of America

15:05 - 15:15 **Second vote and conclusions**
Aurelien Marabelle, Institut Gustave Roussy, Villejuif, France

14:15 - 15:45 **Type: Abstract session** **Room B**
Title: Proffered Paper session 2
 Moderation: Michele Maio, Italy; Eliane Piaggio, France

14:15 - 14:25 **1190 - Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144-01 study**

Martin Wermke¹, J. Chesney², E. Whitman³, H. Kluger⁴, S. Thomas⁵, A. Sarnaik⁶, J. Kirkwood⁷, J. Larkin⁸, J. Weber⁹, O. Hamid¹⁰, F. Graf Finckenstein¹¹, J. Chou¹¹, B. Gastman¹¹, G. Sultur¹¹, X. Wu¹¹, W. Shi¹¹, E. Domingo-Musibay¹², ¹Dresden University, Dresden, Germany, ²Brown Cancer Center, Louisville, United States of America, ³Atlantic Health System, Morristown, United States of America, ⁴Yale Cancer Center, New Haven, United States of America, ⁵Orlando Health Cancer Institute, Orlando, United States of America, ⁶H Lee Moffitt Cancer Center and Research Institute, Tampa, United States of America, ⁷UPMC Hillman Cancer Center, Pittsburgh, United States of America, ⁸The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom, ⁹Laura and Isaac Perlmutter Cancer Center, New York City, United States of America, ¹⁰The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, United States of America, ¹¹Iovance Biotherapeutics, Inc., San Carlos, United States of America, ¹²Masonic Cancer Center, Minneapolis, United States of America

14:25 - 14:40 **Invited Discussant 1190**

Anna Di Giacomo, AOU Senese - Santa Maria delle Scotte, Siena, Italy

14:40 - 14:50 **Q&A**

All Speakers, Geneva, Switzerland

14:50 - 15:00 **480 - Safety and Efficacy of Combined Treatment with Tumor Infiltrating Lymphocytes (TILs) and Oncolytic Adenovirus TILT-123 for Patients with Metastatic Melanoma - Results from a Phase I Trial**

Tine Monberg¹, S. Pakola², B. Dréno³, V. Cervera-Carrascon⁴, E. Ellebæk⁵, M. Donia⁵, A. Khammari³, C. Kistler⁴, J. Manuel Dos Santos⁴, J. Clubb⁴, L. Haybout⁴, B. Albieri⁵, T. Kudling², D. Quixabeira⁴, E. Jirovec², R. Havunen⁴, S. Juteau⁶, S. Sorsa⁴, A. Hemminki⁴, I.M. Svane¹, ¹Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark, ²University of Helsinki, Helsinki, Finland, ³CHU du Nantes, Nantes, Cedex, France, ⁴TILT Biotherapeutics Ltd., Helsinki, Finland, ⁵Department of Oncology, Herlev Hospital, Copenhagen University, Herlev, Denmark, ⁶HUS, Comprehensive Cancer Center, Helsinki, Finland

15:00 - 15:10 **490 - Clinical Experience of Tabelecleucel in Epstein-Barr Virus-Positive Post-transplant Lymphoproliferative Disease (EBV+ PTLD) Involving the Central Nervous System**

R. Baiocchi¹, S. Choquet², M. Ghosh³, E. Orciuolo⁴, John Patton¹, R. Dinavahi⁵, J. Wahlstrom⁵, X. You⁵, S. Zhang⁵, S. Prockop⁶, ¹James Comprehensive Cancer Center, The Ohio State University, Columbus, United States of America, ²Hospitalier Pitié Salpêtrière, Paris, France, ³Michigan Medicine University of Michigan, Ann Arbor, United States of America, ⁴University of Pisa/AOUP, Pisa, Italy, ⁵Atara Biotherapeutics, Thousand Oaks, United States of America, ⁶Boston Children's Hospital/Dana Farber Cancer Institute,, Boston, United States of America

15:10 - 15:25 **Invited Discussant 480 and 490**

George Coukos, UNIL - Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, Switzerland

15:25 - 15:35 **Q&A**

All Speakers, Geneva, Switzerland

14:15 - 15:45	Type: Collaborative session Title: Collaborative session ESMO-SITC Moderation: Jennifer Guerriero, United States of America; John Haanen, Netherlands	Room C
14:15 - 14:20	Welcome and introduction <u>Jennifer Guerriero</u> , Brigham and Women's Hospital, Boston, United States of America	
14:20 - 14:40	Lessons learned from combination immunotherapy in melanoma <u>John Haanen</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands	
14:40 - 14:45	Q&A <u>All Speakers</u> , Geneva, Switzerland	
14:45 - 15:05	Lessons learned from combination immunotherapy in GU cancers <u>Mathieu Rouanne</u> , Columbia University, New York, United States of America	
15:05 - 15:10	Q&A <u>All Speakers</u> , Geneva, Switzerland	
15:10 - 15:30	Deep immunophenotyping to identify biomarkers and therapeutic targets in solid tumors <u>Thomas Marron</u> , Icahn School of Medicine at Mount Sinai, New York, United States of America	
15:30 - 15:35	Q&A <u>All Speakers</u> , Geneva, Switzerland	
15:35 - 15:45	Panel discussion: Biological stratification of patients for better immunotherapy <u>All Speakers</u> , Geneva, Switzerland	

16:15 - 17:45	Type: Educational session Title: Genitourinary tumours Moderation: Guillermo Antonio De Velasco Oria, Spain; Mathieu Rouanne, United States of America	Room A
16:15 - 16:35	I-O in all patients for mRCC <u>Guillermo Antonio De Velasco Oria</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
16:35 - 16:55	Searching for I-O in prostate cancer? <u>Alice Bernard-Tessier</u> , Institut Gustave Roussy, Villejuif, France	
16:55 - 17:15	Where I-O makes sense in urothelial carcinoma <u>Thomas Powles</u> , St. Bartholomew's Hospital - Barts Health NHS Trust, London, United Kingdom	
17:15 - 17:35	I-O in NMIBC: Go/no-go <u>Geraldine Pignot</u> , IPC - Institut Paoli-Calmettes, Marseille, France	
17:35 - 17:45	Q&A and discussion <u>All Speakers</u> , Geneva, Switzerland	
16:15 - 17:45	Type: Educational session Title: Improved immune monitoring for better drug development in I-O Moderation: Aurelien Marabelle, France; Laurence Buisseret, Belgium	Room B
16:15 - 16:35	Opportunities for multiparametric monitoring with imaging mass cytometry (Cytof) <u>Bernd Bodenmiller</u> , University of Zurich, Zurich, Switzerland	
16:35 - 16:55	Value of fresh material assessment in early phase clinical trials <u>Aurelien Marabelle</u> , Institut Gustave Roussy, Villejuif, France	
16:55 - 17:15	Integrated multi omic correlation with clinical response in I-O <u>Michele Ceccarelli</u> , Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, United States of America	
17:15 - 17:35	A deep dive into transcriptomics of immune cells thanks to single cell RNAseq <u>Eliane Piaggio</u> , Institut Curie, Paris, France	
17:35 - 17:45	Q&A and discussion <u>All Speakers</u> , Geneva, Switzerland	

16:15 - 17:45	Type: Special session Title: Co-formulation bispecific approaches Moderation: Thomas Marron, United States of America; Tanaya Shree, United States of America	Room C
16:15 - 16:35	Insights from tebentafusp, the first TCR therapeutic <u>David Berman</u> , Immunocore LLC, Rockville, United States of America	
16:35 - 16:55	Anti-DLL3 x CD3 BiTe <u>Gregory Friberg</u> , Amgen (Europe) GmbH, Risch-Rotkreuz, Switzerland	
16:55 - 17:15	Anti-CD30 bispecific (Fc engager) programme <u>Yago Nieto</u> , The University of Texas M. D. Anderson Cancer Center, Houston, United States of America	
17:15 - 17:35	Teclistamab as a challenge to CAR T <u>Tobias Kampfenkel</u> , Witten, Germany	
17:35 - 17:45	Q&A and discussion <u>All Speakers</u> , Geneva, Switzerland	

08.12.2023

08:30 - 10:00 **Type: Educational session** **Room A**
Title: Gastrointestinal tumours
 Moderation: Elizabeth Smyth, United Kingdom; Thierry André, France

08:30 - 08:50 **Immunotherapy for metastatic upper GI cancer**
Elizabeth Smyth, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

08:50 - 09:10 **Immunotherapy for metastatic colorectal cancer**
Antonio Avallone, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, Italy

09:10 - 09:30 **Perioperative immunotherapy for GI cancer**
Thierry André, Hopital Saint-Antoine, Paris, France

09:30 - 09:50 **Cellular therapy for GI cancer**
Changsong Qi, Peking University Cancer Hospital and Institute, Beijing, China

09:50 - 10:00 **Q&A and discussion**
All Speakers, Geneva, Switzerland

08:30 - 10:00 **Type: Educational session** **Room C**
Title: New targets and tumour microenvironment
 Moderation: Ignacio Melero, Spain; Laurence Zitvogel, France

08:30 - 08:50 **Tumour inflammation as a target**
Cecilia Garlanda, Humanitas University, Pieve Emanuele, Italy

08:50 - 09:10 **Microflora interventions for immunotherapy**
Laurence Zitvogel, Institut Gustave Roussy, Villejuif, France

09:10 - 09:30 **Crosspriming in cancer immunotherapy**
Ignacio Melero, Clinica Universidad de Navarra, Pamplona, Spain

09:30 - 09:50 **NK targets for cancer immunotherapy**
Eric Vivier, Aix-Marseille University - Faculté de Médecine - Timone, Marseille, France

09:50 - 10:00 **Q&A and discussion**
All Speakers, Geneva, Switzerland

09:00 - 10:00 **Type: Young Oncologists (YO) session** **Room K**
Title: YO Clinical case discussion
 Moderation: Maria Kfoury, France; Angelika Starzer, Austria; Kok Haw Jonathan Lim, United Kingdom

09:00 - 09:10 **Cytokine release syndrome and management**
Michael Saerens, Ghebt, Belgium

09:10 - 09:25 **Discussion**
Alessandra Curioni-Fontecedro, Cantonal Hospital Fribourg, Fribourg, Switzerland

09:25 - 09:35 **Survivorship: Long-term I-O toxicities**
Alexandre Bertucci, Institute Paoli Calmettes, Marseille, France

09:35 - 09:50 **Discussion**
Jonathan Lim, The Francis Crick Institute, London, United Kingdom

09:50 - 10:00 **Q&A**

10:30 - 12:00 **Type: Educational session** **Room A**
Title: Haematological malignancies
 Moderation: Tanaya Shree, United States of America; Michele Maio, Italy

10:30 - 10:55 **The immunology of immune cell cancers**
Tanaya Shree, OHSU - Oregon Health Science University, Portland, United States of America

10:55 - 11:20 **Current state and future prospects of immunotherapy for multiple myeloma**
Paula Rodriguez-Otero, Janssen Pharmaceuticals, Inc, Horsham, United States of America

11:20 - 11:45 **Current state and future prospects of immunotherapy for lymphoid malignancies**
Guillaume Manson, CHU de Rennes - Hopital Pontchaillou, Rennes, France

11:45 - 12:00 **Q&A and discussion**
All Speakers, na, Switzerland

10:30 - 12:00	Type: Educational session Title: Breast cancer Moderation: Jennifer Guerriero, United States of America; Laurence Buisseret, Belgium	Room C
10:30 - 10:50	Immune biology in breast cancer <u>Emanuela Romano</u> , Institut Curie, Paris, France	
10:50 - 11:10	Development of non-T cell immunotherapy in breast cancer <u>Jennifer Guerriero</u> , Brigham and Women's Hospital, Boston, United States of America	
11:10 - 11:30	Clinical overview of immunotherapy in breast cancer <u>Laurence Buisseret</u> , Institute Jules Bordet, Brussels, Belgium	
11:30 - 11:50	Biomarkers for immunotherapy in breast cancer <u>Leonie Voorwerk</u> , Netherlands Cancer Institute, Amsterdam, Netherlands	
11:50 - 12:00	Q&A and discussion <u>All Speakers</u> , Geneva, Switzerland	
12:15 - 13:00	Type: Young Oncologists (YO) session Title: YO Vesalius talk: Developing expertise in immunotherapy research: From trial design to the use of biomarkers Moderation: Kok Haw Jonathan Lim, United Kingdom; Maria Kfoury, France; Angelika Starzer, Austria	Room K
12:15 - 13:00	Panellist <u>John Haanen</u> ¹ , S. Peters ² , I.M. Svane ³ , ¹ NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, ² CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³ Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark	
13:00 - 13:45	Panellist <u>Solange Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland	
13:45 - 14:30	Panellist <u>Inge Marie Svane</u> , Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark	

13:00 - 14:30 **Type: Educational session** **Room A**
Title: Gynaecological malignancies
 Moderation: Ana Oaknin, Spain; Maria Kfoury, France

13:00 - 13:20 **A deep look at checkpoints inhibitors in ovarian cancer treatment: Why this couple doesn't seem to work**
Isabelle Ray-Coquard, Centre Léon Bérard, Lyon, France

13:20 - 13:40 **The immunotherapy arrival: A paradigm shift in advanced endometrial cancer treatment**
Domenica Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, Italy

13:40 - 14:00 **Is immunotherapy beating advanced cervical cancer?**
Ana Oaknin, Vall d'Hebron University Hospital, Barcelona, Spain

14:00 - 14:20 **Are PD-L1 and MMR status paving the way of personalised medicine in gynaecological tumours?**
Koen Van De Vijver, UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium

14:20 - 14:30 **Q&A and discussion**
All Speakers, Geneva, Switzerland

13:00 - 14:30 **Type: Educational session** **Room C**
Title: Epigenetic remodelling
 Moderation: Michele Maio, Italy; Daniela Matei, United States of America

13:00 - 13:20 **T cell epigenetics**
Andrea Anichini, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

13:20 - 13:40 **cfDNA epigenetics**
Daniel De Carvalho, Princess Margaret Cancer Centre, Toronto, Canada

13:40 - 14:00 **Epigenetic reprogramming of CAR T cells for functional persistence in solid tumours**
Michael Saitakis, Institut Curie, Paris, France

14:00 - 14:20 **Epigenetically based I-O combinations in the clinic**
Daniela Matei, Northwestern University Feinberg School of Medicine, Chicago, United States of America

14:20 - 14:30 **Q&A and discussion**
All Speakers, Geneva, Switzerland